<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01557244</url>
  </required_header>
  <id_info>
    <org_study_id>A0221047</org_study_id>
    <secondary_id>2010-022475-55</secondary_id>
    <nct_id>NCT01557244</nct_id>
  </id_info>
  <brief_title>A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition</brief_title>
  <official_title>A 24-WEEK RANDOMIZED, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to find out if the medicine fesoterodine is a useful treatment&#xD;
      in children with bladder muscle overactivity caused by a neurological condition. Children&#xD;
      will be aged 6 to 17 years old. This is done by finding out how well it works, what the body&#xD;
      does to fesoterodine, what side effects are experienced and the safety of fesoterodine. It&#xD;
      will be compared with the medicine oxybutynin, which is already available for treating the&#xD;
      condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2012</start_date>
  <completion_date type="Actual">February 13, 2020</completion_date>
  <primary_completion_date type="Actual">November 7, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Maximum cystometric bladder capacity (in milliliter) was defined as maximal tolerable cystometric capacity, until voiding or leaking begins or at a pressure of &gt;=40 centimeter (cm) water (H2O).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Detrusor Pressure at Maximum Bladder Capacity at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Detrusor pressure (in cm H2O) at maximum urinary bladder capacity was measured using urodynamic testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Shift From Baseline at Week 12 in Involuntary Detrusor Contractions (IDC): Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>In this outcome measure, shift data have been reported using 4 categories: (1) number of participants who did not have IDC at Baseline and at Week 12, (2) number of participants who did not have IDC at Baseline but had IDC at Week 12, (3) number of participants who had IDC at Baseline but no IDC at Week 12, and (4) number of participants who had IDC at Baseline and at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bladder Volume at First Involuntary Detrusor Contraction (IDC) at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Bladder volume (in milliliter) at first IDC was measured using urodynamic testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bladder Compliance at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Bladder compliance was defined as change in bladder volume in milliliter (mL) divided by change in bladder pressure in cm H2O (during the same time when change in bladder volume was estimated).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The mean number of micturitions per 24 hours were calculated as the total number of micturitions divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 micturitions at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Catheterizations Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The mean number of catheterizations per 24 hours were calculated as the total number of catheterizations divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on; even if it was not a full 24 hours period. This outcome measure was only calculated for participants with &gt;0 catheterizations at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturitions or Catheterizations Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The mean number of micturitions or catheterizations combined per 24 hours were calculated as the total number of micturitions and catheterizations combined divided by the total number of diary days collected at the assessment point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hour (hrs) period. This outcome was evaluated in those participants who had micturitions or catheterizations &gt;0 at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The mean number of incontinence episodes per 24 hours were calculated as the total number of incontinence episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hours period. This outcome measure was only calculated for participants with &gt;0 incontinence episodes at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The mean number of urgency episodes per 24 hours were calculated as the total number of urgency episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hours period. Urgency episodes were defined as urgency marked as 'yes' in the diary. This outcome measure was only calculated for participants with &gt;0 urgency episodes at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Volume Voided Per Micturition at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The mean voided volume per micturition was calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume greater than 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Volume Voided Per Catheterization at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The mean volume per catheterization was calculated as sum of voided volume divided by the total number of catheterization, with a recorded voided volume greater than 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Volume Voided Per Micturition or Catheterization at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The mean voided volume per micturition or catheterization was calculated as sum of voided volume divided by the total number of micturition or catheterization episodes with a recorded voided volume greater than 0. This outcome was evaluated in those participants who had micturitions or catheterizations &gt;0 at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline up to Week 12</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both all serious and non-serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Safety Extension Phase</measure>
    <time_frame>Week 12 up to Week 26 (including 2 weeks of follow up after last dose)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both all serious and non-serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Acuity at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Visual acuity (VA) was assessed using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA/Snellen ratio = distance between the chart and participant, divided by the distance at which participant was able to see or read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure data have been reported for right and left eye separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Acuity at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>VA was assessed using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA/Snellen ratio = distance between the chart and participant, divided by the distance at which participant was able to see or read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure data have been reported for right and left eye separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Accommodation at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The visual accommodation was the distance for each eye at which vision became blurred and was calculated as the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Accommodation at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The visual accommodation is the distance for each eye at which vision became blurred and was calculated as the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>CBCL: 120 items questionnaire answered by parent/caregiver of child to assess a child's behavioral, emotional problems. Scale for each item: 0= not true, 1= somewhat/sometimes true, 2= very true/often true. Out of 120 items, 103 were categorized into 8 domains; aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems=anxious/depressed + withdrawn + somatic complaints; Externalizing problems=rule-breaking + aggressive behavior. Total problems=8 domains + other 17 items. Raw scores for each domain, summary and total problems=sum of scores of related items. Using Assessment Data Manager (ADM) tool raw scores transformed/derived into standard T-scores, range: each domain=50 to 100, internalizing problems=34 to 100, externalizing problems=33 to 100, total problems=24 to 100. Lower T-score for each 8 domains, 2 summary and total problems scores=better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>CBCL: 120 items questionnaire answered by parent/caregiver of child to assess a child's behavioral, emotional problems. Scale for each item: 0= not true, 1= somewhat/sometimes true, 2= very true/often true. Out of 120 items, 103 were categorized into 8 domains; aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems=anxious/depressed + withdrawn + somatic complaints; Externalizing problems=rule-breaking + aggressive behavior. Total problems=8 domains + other 17 items. Raw scores for each domain, summary and total problems=sum of scores of related items. Using Assessment Data Manager (ADM) tool raw scores transformed/derived into standard T-scores, range: each domain=50 to 100, internalizing problems=34 to 100, externalizing problems=33 to 100, total problems=24 to 100. Lower T-score for each 8 domains, 2 summary and total problems scores=better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Child Behavior Checklist Total Score (Raw Score) at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>CBCL: It consisted of 120 items on behavior and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0= not true, 1= somewhat/sometimes true, 2= very/often true. 103 items were classified in 8 domains: aggressive behavior: total score range (TSR)= 0 to 36, anxious/depressed: TSR= 0 to 26, attention problems: TSR= 0 to 20, rule-breaking behavior: TSR= 0 to 34, social problems: TSR= 0 to 22, somatic complaints: TSR= 0 to 22, thought problems: TSR= 0 to 30, withdrawn (TSR)= 0 to 16. Rule-breaking and aggressive behavior summarized to externalizing problems with a TSR= 0 to 70. Anxious/depressed, withdrawn, somatic complaints summarized to internalizing problems with a TSR= 0 to 64. All 103 items of 8 domains and other 17 remaining items were combined to give total problems TSR = 0 to 240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary and total problems= better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Child Behavior Checklist Total Score (Raw Score) at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>CBCL: It consisted of 120 items on behavior and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0= not true, 1= somewhat/sometimes true, 2= very/often true. 103 items were classified in 8 domains: aggressive behavior: total score range (TSR)= 0 to 36, anxious/depressed: TSR= 0 to 26, attention problems: TSR= 0 to 20, rule-breaking behavior: TSR= 0 to 34, social problems: TSR= 0 to 22, somatic complaints: TSR= 0 to 22, thought problems: TSR= 0 to 30, withdrawn (TSR)= 0 to 16. Rule-breaking and aggressive behavior summarized to externalizing problems with a TSR= 0 to 70. Anxious/depressed, withdrawn, somatic complaints summarized to internalizing problems with a TSR= 0 to 64. All 103 items of 8 domains and other 17 remaining items were combined to give total problems TSR = 0 to 240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary and total problems= better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting Pre-defined Criteria for Vital Signs Values From Baseline Through Week 12: Active Comparator/Efficacy Phase</measure>
    <time_frame>Baseline up to Week 12</time_frame>
    <description>Pre-defined criteria for vital signs: 1) a) systolic blood pressure (SBP) of &lt;90 millimeter of mercury (mmHg), b) change &gt;=30 mmHg increase, c) change &gt;=30 mmHg decrease; 2) a) diastolic blood pressure (DBP) of &lt;50 mmHg, b) change &gt;=20 mmHg increase, c) change &gt;=20 mmHg decrease; 3) a) pulse rate value of &lt;40 beats per minute (bpm), b) pulse rate value &gt;120 bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting Pre-defined Criteria for Vital Signs Values From Baseline Through Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Pre-defined criteria for vital signs: 1) a) systolic blood pressure (SBP) of &lt;90 millimeter of mercury (mmHg), b) change &gt;=30 mmHg increase, c) change &gt;=30 mmHg decrease; 2) a) diastolic blood pressure (DBP) of &lt;50 mmHg, b) change &gt;=20 mmHg increase, c) change &gt;=20 mmHg decrease; 3) a) pulse rate value of &lt;40 beats per minute (bpm), b) pulse rate value &gt;120 bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Urinary Tract Infections (UTI): Active Comparator/Efficacy Phase</measure>
    <time_frame>Week 1 up to Week 12</time_frame>
    <description>Clinically significant UTI, counted as an adverse event was defined as: positive urine culture with a uropathogen (defined as &gt;=10^5 colony forming unit per milliliter [CFU/mL]) and the presence of symptoms, or pyuria (defined as &gt;50 white blood cells [WBC] per high-pass filter [hpf]) and the presence of symptoms, or positive urine culture with a uropathogen (defined as &gt;=10^5 CFU/mL) with or without symptoms in a participant with a documented history of vesicoureteral reflux (VUR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Urinary Tract Infections (UTI): Safety Extension Phase</measure>
    <time_frame>Week 12 up to Week 26</time_frame>
    <description>Clinically significant UTI, counted as an adverse event was defined as: positive urine culture with a uropathogen (defined as &gt;=10^5 CFU/mL) and the presence of symptoms, or pyuria (defined as &gt;50 WBC per hpf and the presence of symptoms, or positive urine culture with a uropathogen (defined as &gt;=10^5 CFU/mL) with or without symptoms in a participants with a documented history of VUR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities: Active Comparator/Efficacy Phase</measure>
    <time_frame>Week 1 up to Week 12</time_frame>
    <description>Hematology: hemoglobin, hematocrit, erythrocytes &lt;0.8*lower limit of normal (LLN), platelets&lt;0.5*LLN&gt;1.75*upper limit of normal (ULN), leukocytes &lt;0.6*LLN&gt;1.5*ULN, lymphocytes, neutrophils, &lt;0.8*LLN &gt;1.2*ULN, basophils, eosinophils, monocytes monocytes/leukocytes &gt;1.2*ULN. Clinical chemistry: bilirubin, direct, bilirubin &gt;1.5*ULN, aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase&gt;3.0*ULN, protein, albumin, phosphate &lt;0.8*LLN &gt;1.2*ULN, blood urea nitrogen, creatinine &gt;1.3*ULN, urate &gt;1.2*ULN, sodium&lt;0.95*LLN&gt;1.05*ULN, potassium, chloride, calcium bicarbonate&lt;0.9*LLN&gt;1.1*ULN, glucose&lt;0.6*LLN&gt;1.5*ULN, creatine kinase &gt;2.0*ULN. Urinalysis: specific gravity &lt;1.003&gt;1.030, pH &lt;4.5&gt;8, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite, &gt;=1, urine erythrocytes, urine leukocytes &gt;=20, epithelial cells &gt;=6, bacteria &gt;20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities: Safety Extension Phase</measure>
    <time_frame>Week 12 up to Week 26</time_frame>
    <description>Hematology: hemoglobin, hematocrit, erythrocytes &lt;0.8*lower limit of normal (LLN), platelets&lt;0.5*LLN&gt;1.75*upper limit of normal (ULN), leukocytes &lt;0.6*LLN&gt;1.5*ULN, lymphocytes, neutrophils, &lt;0.8*LLN &gt;1.2*ULN, basophils, eosinophils, monocytes monocytes/leukocytes &gt;1.2*ULN. Clinical chemistry: bilirubin, direct, bilirubin &gt;1.5*ULN, aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase&gt;3.0*ULN, protein, albumin, phosphate &lt;0.8*LLN &gt;1.2*ULN, blood urea nitrogen, creatinine &gt;1.3*ULN, urate &gt;1.2*ULN, sodium&lt;0.95*LLN&gt;1.05*ULN, potassium, chloride, calcium bicarbonate&lt;0.9*LLN&gt;1.1*ULN, glucose&lt;0.6*LLN&gt;1.5*ULN, creatine kinase &gt;2.0*ULN. Urinalysis: specific gravity &lt;1.003&gt;1.030, pH &lt;4.5&gt;8, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite, &gt;=1, urine erythrocytes, urine leukocytes &gt;=20, epithelial cells &gt;=6, bacteria &gt;20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-Void Residual (PVR) Volume at Weeks 4, 12: Active Comparator Phase/Efficacy Phase</measure>
    <time_frame>Baseline, Week 4, 12</time_frame>
    <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-Void Residual Volume at Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Changes in Physical Examination Findings From Baseline to Week 12: Active Comparator/Efficacy Phase</measure>
    <time_frame>Baseline up to Week 12</time_frame>
    <description>Physical examination included assessment of the general appearance and the skin, head, ears, eyes, nose, mouth, throat, respiratory, cardiovascular, gastrointestinal, musculoskeletal and neurological systems. Clinically relevant changes in physical findings were assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Changes in Physical Examination Findings From Baseline to Week 24: Safety Extension Phase</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Physical examination included assessment of the general appearance and the skin, head, ears, eyes, nose, mouth, throat, respiratory, cardiovascular, gastrointestinal, musculoskeletal and neurological systems. Clinically relevant changes in physical findings were assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption Rate Constant (Ka) of Fesoterodine</measure>
    <time_frame>Week 4, Day 1: pre-dose (when dose administered at clinic) or if dose taken at home up to 3 hours before coming to the clinic, sampling just after arrival at clinic, 5 hours post-dose, 8-10 hours post-dose (if participants remained at clinic)</time_frame>
    <description>Absorption rate constant is used to determine rate at which drug is entering into body. Pharmacokinetic (PK) analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Fesoterodine</measure>
    <time_frame>Week 4, Day 1: pre-dose (when dose administered at clinic) or if dose taken at home up to 3 hours before coming to the clinic, sampling just after arrival at clinic, 5 hours post-dose, 8-10 hours post-dose (if participants remained at clinic)</time_frame>
    <description>Clearance determines the rate at which a drug is metabolized or eliminated by normal biological processes. PK analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vd) of Fesoterodine</measure>
    <time_frame>Week 4, Day 1: pre-dose (when dose administered at clinic) or if dose taken at home up to 3 hours before coming to the clinic, sampling just after arrival at clinic, 5 hours post-dose, 8-10 hours post-dose (if participants remained at clinic)</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PK analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Urinary Bladder, Neurogenic</condition>
  <arm_group>
    <arm_group_label>Fesoterodine PR 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine PR 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxybutynin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxybutynin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine BIC 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine BIC 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine PR 4 mg</intervention_name>
    <description>Fesoterodine 4 mg tablet once daily for 24 weeks</description>
    <arm_group_label>Fesoterodine PR 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine PR 8 mg</intervention_name>
    <description>Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.</description>
    <arm_group_label>Fesoterodine PR 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine PR 8 mg</intervention_name>
    <description>Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.</description>
    <arm_group_label>Fesoterodine PR 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin</intervention_name>
    <description>Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.</description>
    <arm_group_label>Oxybutynin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine PR</intervention_name>
    <description>Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.</description>
    <arm_group_label>Oxybutynin</arm_group_label>
    <other_name>Safety extension phase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine BIC 2 mg</intervention_name>
    <description>Fesoterodine BIC 2 mg tablet once daily for 24 weeks.</description>
    <arm_group_label>Fesoterodine BIC 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine BIC 4 mg</intervention_name>
    <description>Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.</description>
    <arm_group_label>Fesoterodine BIC 4 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged 6 to 17 years old&#xD;
&#xD;
          -  Subjects with stable neurological disease and neurogenic detrusor overactivity&#xD;
&#xD;
          -  Subjects using clean intermittent catheterization may participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant medications which may increase the risk to subjects or confound study&#xD;
             results&#xD;
&#xD;
          -  Other medical conditions which may increase the risk to subjects or confound study&#xD;
             results&#xD;
&#xD;
          -  Contraindications to the use of fesoterodine or oxybutynin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHOC Children's Urology Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Urology, P.A.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Judson L. Hawk Jr. M.D.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Outpatient Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Iowa Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Chapel Hill Memorial Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Memorial Hospital Pediatric Clinic</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Liberty Township</city>
        <state>Ohio</state>
        <zip>45044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Radiology</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharma Resource</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urological Associates, Inc</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urological Associates, Inc.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen, Urologie</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hpital Universitaire des Enfants Reine Fabiola</name>
      <address>
        <city>Bruxelles</city>
        <state>Bruxelles-capitale</state>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire (CHU) Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallinn Children's Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Est - Hopital Femme Mere Enfant</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hpitaux Pdiatriques de Nice CHU-Lenval</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH</name>
      <address>
        <city>Mnchengladbach</city>
        <state>Nordrhein-westfalen</state>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larisa/ Urology Department</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aristotle University of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Christian Medical College and Hospital</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. - Ospedale &quot;Casa Sollievo della Sofferenza&quot; - Dipartimento Scienze Chirurgiche</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Brotzu, Dipartimento di Medicina interna-</name>
      <address>
        <city>Cagliari</city>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Ges</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULSS 6 VICENZA - Ospedale San Bortolo di Vicenza</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Children's Health and Medical Center</name>
      <address>
        <city>Obu</city>
        <state>Aichi</state>
        <zip>474 8710</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba Children's Hospital</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba, Japan</state>
        <zip>266-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo prefectural Kobe Children's Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>3908621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center and Research Institute for Maternal and Child Health</name>
      <address>
        <city>Izumi-shi</city>
        <state>Osaka</state>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Koshigaya Hospital</name>
      <address>
        <city>Koshigaya</city>
        <state>Saitama</state>
        <zip>343-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Children's Hospital</name>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <zip>420 8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hospital / Urology</name>
      <address>
        <city>Shimotsuga-gun</city>
        <state>Tochigi</state>
        <zip>321 0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329 0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital / Urology</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan-si</city>
        <state>Gyeongsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kaunas klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Selayang</name>
      <address>
        <city>Batu Caves</city>
        <state>Selangor</state>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine Children's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <state>NCR</state>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chorob Nerek i Nadcisnienia Dzieci i Mlodziezy</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Gabinet Lekarski Pawe Kroll</name>
      <address>
        <city>Poznan</city>
        <zip>61-512</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University</name>
      <address>
        <city>Kazan</city>
        <state>Republic OF Tatarstan</state>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Republican Clinical Hospital, Department of Pediatric Surgery</name>
      <address>
        <city>Kazan</city>
        <zip>420138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Urology named after N.A.Lopatkin of the Hertsen Federal Medical</name>
      <address>
        <city>Moscow</city>
        <zip>105425</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBNU Scientific center of children health</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSS - Research Clinical Institute of Pediatrics n.a. Academician Y.E.Veltishchev GBOU VPO</name>
      <address>
        <city>Moscow</city>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. BREZA MEDICAL s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>831 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny ustav detskych chorob</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Cross Children's Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western CAPE</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maraon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nio Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska barnsjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitts-Kinderspital beider Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Necmettin Erbakan Universitesi Meram Tip Fakultesi</name>
      <address>
        <city>Konya</city>
        <state>Konya / Turkey</state>
        <zip>42080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tip Fakultesi Ibni Sina Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Uroloji Anabilim Dali</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221047&amp;StudyName=A%20Study%20To%20Find%20Out%20How%20Fesoterodine%20Works%20In%20Children%20Aged%206%20To%2017%20Years%20With%20Bladder%20Overactivity%20Caused%20By%20A%20Neurological%20Condi</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 15, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2012</study_first_posted>
  <results_first_submitted>October 23, 2020</results_first_submitted>
  <results_first_submitted_qc>January 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurogenic detrusor overactivity</keyword>
  <keyword>neurogenic bladder</keyword>
  <keyword>neuropathic bladder</keyword>
  <keyword>neurologic disease</keyword>
  <keyword>fesoterodine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
    <mesh_term>Oxybutynin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 3, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT01557244/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT01557244/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study had 2 cohorts: cohort 1 had participants with body weight greater than (&gt;) 25 kilogram (kg) and cohort 2 had participants with body weight less than or equal to (&lt;=) 25 kg. There were 2 phases in each cohort: cohort 1- active comparator phase followed by safety extension phase; cohort 2- efficacy phase followed by safety extension phase.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Fesoterodine 4 mg</title>
          <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 milligram (mg) prolonged release (PR) tablet orally once daily for 12 weeks in active comparator phase. Active comparator phase was followed by safety extension phase, where participants continued to receive fesoterodine 4 mg PR tablet orally once daily for another 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Fesoterodine 4 mg Then 8 mg</title>
          <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week and if this dose was tolerated well, participants received fesoterodine 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study. Active comparator phase was followed by safety extension phase, where participants continued to receive fesoterodine 8 mg PR tablet orally once daily for another 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1: Oxybutynin</title>
          <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin extended release (ER) tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 1: Oxybutynin Then Fesoterodine 4 mg</title>
          <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 1: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
          <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated then participants were withdrawn from the study.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 2: Fesoterodine 2 mg</title>
          <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg beads-in-capsule (BIC) capsule orally once daily for 12 weeks in efficacy phase. Efficacy phase was followed by safety extension phase, where participants continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 2: Fesoterodine 2 mg Then 4 mg</title>
          <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if this dose was tolerated well, participants received fesoterodine 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study. Efficacy phase was followed by safety extension phase, where participants continued to receive fesoterodine 4 mg BIC capsule orally once daily for another 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Active Comparator/Efficacy Phase:12Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="28"/>
                <participants group_id="P7" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="28"/>
                <participants group_id="P7" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal By Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication Error Without Associated AEs</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Clinical Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Meet Randomization Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Safety Extension Phase: 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0">Did not receive oxybutynin in safety extension phase.</participants>
                <participants group_id="P4" count="16">Allocated from oxybutynin arm to this arm by investigator in safety extension phase.</participants>
                <participants group_id="P5" count="20">Allocated from oxybutynin arm to this arm by investigator in safety extension phase.</participants>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal By Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication Error Without Associated AEs</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Clinical Response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Fesoterodine 4 mg</title>
          <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase. Active comparator phase was followed by safety extension phase, where participants continued to receive fesoterodine 4 mg PR tablet orally once daily for another 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1: Fesoterodine 4 mg Then 8 mg</title>
          <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week and if this dose was tolerated well, participants received fesoterodine 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study. Active comparator phase was followed by safety extension phase, where participants continued to receive fesoterodine 8 mg PR tablet orally once daily for another 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1: Oxybutynin</title>
          <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2: Fesoterodine 2 mg</title>
          <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg beads-in-capsule (BIC) capsule orally once daily for 12 weeks in efficacy phase. Efficacy phase was followed by safety extension phase, where participants continued to receive fesoterodine 2 mg BIC capsules orally once daily for another 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 2: Fesoterodine 2 mg Then 4 mg</title>
          <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if this dose was tolerated well, participants received fesoterodine 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study. Efficacy phase was followed by safety extension phase, where participants continued to receive fesoterodine 4 mg BIC capsule orally once daily for another 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="29"/>
            <count group_id="B6" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&gt;=6-9 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=10-12 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=13-17 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>Maximum cystometric bladder capacity (in milliliter) was defined as maximal tolerable cystometric capacity, until voiding or leaking begins or at a pressure of &gt;=40 centimeter (cm) water (H2O).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>Maximum cystometric bladder capacity (in milliliter) was defined as maximal tolerable cystometric capacity, until voiding or leaking begins or at a pressure of &gt;=40 centimeter (cm) water (H2O).</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data.</population>
          <units>milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.12" lower_limit="28.84" upper_limit="87.39"/>
                    <measurement group_id="O2" value="83.36" lower_limit="54.22" upper_limit="112.49"/>
                    <measurement group_id="O3" value="87.17" lower_limit="56.82" upper_limit="117.53"/>
                    <measurement group_id="O4" value="23.49" lower_limit="3.03" upper_limit="43.95"/>
                    <measurement group_id="O5" value="40.17" lower_limit="20.84" upper_limit="59.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an analysis of covariance (ANCOVA) model with terms for treatment group, baseline maximum cystometric bladder capacity and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on ANCOVA model with terms for treatment group, baseline maximum cystometric bladder capacity and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline maximum cystometric bladder capacity and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Least square (LS) Mean</param_type>
            <param_value>-29.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-71.42</ci_lower_limit>
            <ci_upper_limit>13.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-3.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.87</ci_lower_limit>
            <ci_upper_limit>38.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Detrusor Pressure at Maximum Bladder Capacity at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>Detrusor pressure (in cm H2O) at maximum urinary bladder capacity was measured using urodynamic testing.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Detrusor Pressure at Maximum Bladder Capacity at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>Detrusor pressure (in cm H2O) at maximum urinary bladder capacity was measured using urodynamic testing.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>cm H2O</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.86" lower_limit="-7.60" upper_limit="1.87"/>
                    <measurement group_id="O2" value="-1.57" lower_limit="-6.25" upper_limit="3.12"/>
                    <measurement group_id="O3" value="-2.39" lower_limit="-7.27" upper_limit="2.48"/>
                    <measurement group_id="O4" value="-2.74" lower_limit="-10.62" upper_limit="5.15"/>
                    <measurement group_id="O5" value="-9.73" lower_limit="-17.18" upper_limit="-2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline detrusor pressure at maximum bladder capacity and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2334</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline detrusor pressure at maximum bladder capacity and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5087</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline detrusor pressure at maximum bladder capacity and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3333</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.28</ci_lower_limit>
            <ci_upper_limit>6.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.96</ci_lower_limit>
            <ci_upper_limit>7.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Shift From Baseline at Week 12 in Involuntary Detrusor Contractions (IDC): Active Comparator Phase/Efficacy Phase</title>
        <description>In this outcome measure, shift data have been reported using 4 categories: (1) number of participants who did not have IDC at Baseline and at Week 12, (2) number of participants who did not have IDC at Baseline but had IDC at Week 12, (3) number of participants who had IDC at Baseline but no IDC at Week 12, and (4) number of participants who had IDC at Baseline and at Week 12.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shift From Baseline at Week 12 in Involuntary Detrusor Contractions (IDC): Active Comparator Phase/Efficacy Phase</title>
          <description>In this outcome measure, shift data have been reported using 4 categories: (1) number of participants who did not have IDC at Baseline and at Week 12, (2) number of participants who did not have IDC at Baseline but had IDC at Week 12, (3) number of participants who had IDC at Baseline but no IDC at Week 12, and (4) number of participants who had IDC at Baseline and at Week 12.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline IDC = No; Week 12 IDC = No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline IDC = No; Week 12 IDC = Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline IDC = Yes; Week 12 IDC = No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline IDC = Yes; Week 12 IDC = Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bladder Volume at First Involuntary Detrusor Contraction (IDC) at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>Bladder volume (in milliliter) at first IDC was measured using urodynamic testing.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bladder Volume at First Involuntary Detrusor Contraction (IDC) at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>Bladder volume (in milliliter) at first IDC was measured using urodynamic testing.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.53" lower_limit="2.42" upper_limit="58.64"/>
                    <measurement group_id="O2" value="26.06" lower_limit="2.19" upper_limit="49.92"/>
                    <measurement group_id="O3" value="41.31" lower_limit="15.92" upper_limit="66.70"/>
                    <measurement group_id="O4" value="23.80" lower_limit="-1.60" upper_limit="49.19"/>
                    <measurement group_id="O5" value="31.26" lower_limit="6.85" upper_limit="55.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline bladder volume at first IDC and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0336</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline bladder volume at first IDC and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0327</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline bladder volume at first IDC and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-10.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.75</ci_lower_limit>
            <ci_upper_limit>27.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-15.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.15</ci_lower_limit>
            <ci_upper_limit>19.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bladder Compliance at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>Bladder compliance was defined as change in bladder volume in milliliter (mL) divided by change in bladder pressure in cm H2O (during the same time when change in bladder volume was estimated).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bladder Compliance at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>Bladder compliance was defined as change in bladder volume in milliliter (mL) divided by change in bladder pressure in cm H2O (during the same time when change in bladder volume was estimated).</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>mL per cm H2O</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" lower_limit="-0.48" upper_limit="13.28"/>
                    <measurement group_id="O2" value="5.41" lower_limit="-1.49" upper_limit="12.32"/>
                    <measurement group_id="O3" value="11.36" lower_limit="4.30" upper_limit="18.42"/>
                    <measurement group_id="O4" value="12.44" lower_limit="-0.64" upper_limit="25.53"/>
                    <measurement group_id="O5" value="16.44" lower_limit="4.08" upper_limit="28.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline bladder compliance and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0679</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline bladder compliance and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1233</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline bladder compliance and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-4.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.81</ci_lower_limit>
            <ci_upper_limit>4.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-5.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.85</ci_lower_limit>
            <ci_upper_limit>3.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The mean number of micturitions per 24 hours were calculated as the total number of micturitions divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 micturitions at Baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The mean number of micturitions per 24 hours were calculated as the total number of micturitions divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with &gt;0 micturitions at Baseline.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>micturitions per 24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" lower_limit="-1.88" upper_limit="-0.25"/>
                    <measurement group_id="O2" value="-0.68" lower_limit="-1.44" upper_limit="0.08"/>
                    <measurement group_id="O3" value="-0.97" lower_limit="-1.65" upper_limit="-0.29"/>
                    <measurement group_id="O4" value="-0.37" lower_limit="-1.10" upper_limit="0.36"/>
                    <measurement group_id="O5" value="-0.70" lower_limit="-1.36" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of micturitions per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0116</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of micturitions per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0765</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of micturitions per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0061</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Catheterizations Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The mean number of catheterizations per 24 hours were calculated as the total number of catheterizations divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on; even if it was not a full 24 hours period. This outcome measure was only calculated for participants with &gt;0 catheterizations at Baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Catheterizations Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The mean number of catheterizations per 24 hours were calculated as the total number of catheterizations divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on; even if it was not a full 24 hours period. This outcome measure was only calculated for participants with &gt;0 catheterizations at Baseline.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>catheterizations per 24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-0.63" upper_limit="0.04"/>
                    <measurement group_id="O2" value="-0.32" lower_limit="-0.68" upper_limit="0.03"/>
                    <measurement group_id="O3" value="-0.34" lower_limit="-0.71" upper_limit="0.02"/>
                    <measurement group_id="O4" value="-0.10" lower_limit="-0.50" upper_limit="0.29"/>
                    <measurement group_id="O5" value="-0.22" lower_limit="-0.60" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of catheterizations per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0787</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of catheterizations per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0727</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of catheterizations per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0666</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturitions or Catheterizations Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The mean number of micturitions or catheterizations combined per 24 hours were calculated as the total number of micturitions and catheterizations combined divided by the total number of diary days collected at the assessment point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hour (hrs) period. This outcome was evaluated in those participants who had micturitions or catheterizations &gt;0 at Baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturitions or Catheterizations Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The mean number of micturitions or catheterizations combined per 24 hours were calculated as the total number of micturitions and catheterizations combined divided by the total number of diary days collected at the assessment point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hour (hrs) period. This outcome was evaluated in those participants who had micturitions or catheterizations &gt;0 at Baseline.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>micturitions and catheterizations/24 hrs</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" lower_limit="-1.08" upper_limit="-0.14"/>
                    <measurement group_id="O2" value="-0.60" lower_limit="-1.09" upper_limit="-0.11"/>
                    <measurement group_id="O3" value="-0.75" lower_limit="-1.24" upper_limit="-0.26"/>
                    <measurement group_id="O4" value="-0.24" lower_limit="-0.67" upper_limit="0.19"/>
                    <measurement group_id="O5" value="-0.28" lower_limit="-0.68" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of micturitions and catheterizations combined per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0111</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of micturitions and catheterizations combined per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0171</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of micturitions and catheterizations combined per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0028</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The mean number of incontinence episodes per 24 hours were calculated as the total number of incontinence episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hours period. This outcome measure was only calculated for participants with &gt;0 incontinence episodes at Baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The mean number of incontinence episodes per 24 hours were calculated as the total number of incontinence episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hours period. This outcome measure was only calculated for participants with &gt;0 incontinence episodes at Baseline.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>incontinence episodes per 24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" lower_limit="-0.92" upper_limit="-0.00"/>
                    <measurement group_id="O2" value="-0.89" lower_limit="-1.35" upper_limit="-0.43"/>
                    <measurement group_id="O3" value="-1.01" lower_limit="-1.46" upper_limit="-0.56"/>
                    <measurement group_id="O4" value="-0.38" lower_limit="-0.95" upper_limit="0.20"/>
                    <measurement group_id="O5" value="-0.69" lower_limit="-1.29" upper_limit="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of incontinence episodes per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0496</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of incontinence episodes per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of incontinence episodes per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The mean number of urgency episodes per 24 hours were calculated as the total number of urgency episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hours period. Urgency episodes were defined as urgency marked as 'yes' in the diary. This outcome measure was only calculated for participants with &gt;0 urgency episodes at Baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The mean number of urgency episodes per 24 hours were calculated as the total number of urgency episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hours period. Urgency episodes were defined as urgency marked as 'yes' in the diary. This outcome measure was only calculated for participants with &gt;0 urgency episodes at Baseline.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>urgency episodes per 24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" lower_limit="-1.18" upper_limit="-0.06"/>
                    <measurement group_id="O2" value="-0.50" lower_limit="-1.17" upper_limit="0.17"/>
                    <measurement group_id="O3" value="-0.14" lower_limit="-0.70" upper_limit="0.42"/>
                    <measurement group_id="O4" value="-0.23" lower_limit="-0.84" upper_limit="0.38"/>
                    <measurement group_id="O5" value="-0.62" lower_limit="-1.35" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of urgency episodes per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0298</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of urgency episodes per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1417</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of urgency episodes per 24 hours and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6219</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.24</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Volume Voided Per Micturition at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The mean voided volume per micturition was calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume greater than 0.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Volume Voided Per Micturition at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The mean voided volume per micturition was calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume greater than 0.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>milliliter per micturition</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" lower_limit="-28.05" upper_limit="36.24"/>
                    <measurement group_id="O2" value="19.21" lower_limit="-12.67" upper_limit="51.10"/>
                    <measurement group_id="O3" value="4.15" lower_limit="-22.69" upper_limit="30.98"/>
                    <measurement group_id="O4" value="-12.72" lower_limit="-34.96" upper_limit="9.52"/>
                    <measurement group_id="O5" value="-8.41" lower_limit="-28.27" upper_limit="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7986</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2313</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7571</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.11</ci_lower_limit>
            <ci_upper_limit>42.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>15.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.50</ci_lower_limit>
            <ci_upper_limit>56.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Volume Voided Per Catheterization at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The mean volume per catheterization was calculated as sum of voided volume divided by the total number of catheterization, with a recorded voided volume greater than 0.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Volume Voided Per Catheterization at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The mean volume per catheterization was calculated as sum of voided volume divided by the total number of catheterization, with a recorded voided volume greater than 0.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>milliliter per catheterization</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.47" lower_limit="-1.38" upper_limit="60.32"/>
                    <measurement group_id="O2" value="47.18" lower_limit="14.74" upper_limit="79.62"/>
                    <measurement group_id="O3" value="45.90" lower_limit="11.24" upper_limit="80.55"/>
                    <measurement group_id="O4" value="11.50" lower_limit="-9.87" upper_limit="32.88"/>
                    <measurement group_id="O5" value="1.74" lower_limit="-18.76" upper_limit="22.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per catheterization and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0610</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per catheterization and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per catheterization and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0100</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-16.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.14</ci_lower_limit>
            <ci_upper_limit>30.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.00</ci_lower_limit>
            <ci_upper_limit>48.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Volume Voided Per Micturition or Catheterization at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The mean voided volume per micturition or catheterization was calculated as sum of voided volume divided by the total number of micturition or catheterization episodes with a recorded voided volume greater than 0. This outcome was evaluated in those participants who had micturitions or catheterizations &gt;0 at Baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Volume Voided Per Micturition or Catheterization at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The mean voided volume per micturition or catheterization was calculated as sum of voided volume divided by the total number of micturition or catheterization episodes with a recorded voided volume greater than 0. This outcome was evaluated in those participants who had micturitions or catheterizations &gt;0 at Baseline.</description>
          <population>Full analysis set included all participants who were randomized in the study and received at least 1 dose of study medication and had provided baseline primary endpoint data. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>mL per micturition or catheterization</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.45" lower_limit="-11.49" upper_limit="48.40"/>
                    <measurement group_id="O2" value="55.55" lower_limit="25.80" upper_limit="85.31"/>
                    <measurement group_id="O3" value="36.69" lower_limit="6.95" upper_limit="66.43"/>
                    <measurement group_id="O4" value="7.12" lower_limit="-11.87" upper_limit="26.11"/>
                    <measurement group_id="O5" value="-2.65" lower_limit="-20.22" upper_limit="14.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition or catheterization and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2246</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition or catheterization and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition or catheterization and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0161</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-18.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.00</ci_lower_limit>
            <ci_upper_limit>24.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in LS Mean</param_type>
            <param_value>18.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.93</ci_lower_limit>
            <ci_upper_limit>60.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Active Comparator Phase/Efficacy Phase</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both all serious and non-serious adverse events.</description>
        <time_frame>Baseline up to Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Active Comparator Phase/Efficacy Phase</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both all serious and non-serious adverse events.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Emergent AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Safety Extension Phase</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both all serious and non-serious adverse events.</description>
        <time_frame>Week 12 up to Week 26 (including 2 weeks of follow up after last dose)</time_frame>
        <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase (SEP): Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Safety Extension Phase</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both all serious and non-serious adverse events.</description>
          <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment emergent AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment emergent SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Acuity at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>Visual acuity (VA) was assessed using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA/Snellen ratio = distance between the chart and participant, divided by the distance at which participant was able to see or read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure data have been reported for right and left eye separately.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Acuity at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>Visual acuity (VA) was assessed using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA/Snellen ratio = distance between the chart and participant, divided by the distance at which participant was able to see or read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure data have been reported for right and left eye separately.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>logMAR unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.16"/>
                    <measurement group_id="O2" value="0.11" spread="0.19"/>
                    <measurement group_id="O3" value="0.03" spread="0.11"/>
                    <measurement group_id="O4" value="0.15" spread="0.21"/>
                    <measurement group_id="O5" value="0.10" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Eye: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.11"/>
                    <measurement group_id="O2" value="-0.01" spread="0.10"/>
                    <measurement group_id="O3" value="0.02" spread="0.18"/>
                    <measurement group_id="O4" value="0.03" spread="0.12"/>
                    <measurement group_id="O5" value="-0.00" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.16"/>
                    <measurement group_id="O2" value="0.10" spread="0.17"/>
                    <measurement group_id="O3" value="0.02" spread="0.13"/>
                    <measurement group_id="O4" value="0.16" spread="0.21"/>
                    <measurement group_id="O5" value="0.14" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.13"/>
                    <measurement group_id="O2" value="-0.01" spread="0.10"/>
                    <measurement group_id="O3" value="0.00" spread="0.13"/>
                    <measurement group_id="O4" value="-0.02" spread="0.08"/>
                    <measurement group_id="O5" value="0.00" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Acuity at Week 24: Safety Extension Phase</title>
        <description>VA was assessed using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA/Snellen ratio = distance between the chart and participant, divided by the distance at which participant was able to see or read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure data have been reported for right and left eye separately.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Acuity at Week 24: Safety Extension Phase</title>
          <description>VA was assessed using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA/Snellen ratio = distance between the chart and participant, divided by the distance at which participant was able to see or read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure data have been reported for right and left eye separately.</description>
          <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>logMAR unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.17"/>
                    <measurement group_id="O2" value="-0.02" spread="0.11"/>
                    <measurement group_id="O3" value="-0.01" spread="0.05"/>
                    <measurement group_id="O4" value="0.02" spread="0.13"/>
                    <measurement group_id="O5" value="0.00" spread="0.07"/>
                    <measurement group_id="O6" value="0.01" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.19"/>
                    <measurement group_id="O2" value="-0.01" spread="0.11"/>
                    <measurement group_id="O3" value="0.00" spread="0.08"/>
                    <measurement group_id="O4" value="-0.04" spread="0.09"/>
                    <measurement group_id="O5" value="-0.02" spread="0.07"/>
                    <measurement group_id="O6" value="0.03" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Accommodation at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The visual accommodation was the distance for each eye at which vision became blurred and was calculated as the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Accommodation at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The visual accommodation was the distance for each eye at which vision became blurred and was calculated as the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.88" spread="7.39"/>
                    <measurement group_id="O2" value="15.94" spread="18.64"/>
                    <measurement group_id="O3" value="9.59" spread="5.05"/>
                    <measurement group_id="O4" value="9.67" spread="16.71"/>
                    <measurement group_id="O5" value="8.17" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Eye: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="7.45"/>
                    <measurement group_id="O2" value="7.77" spread="45.53"/>
                    <measurement group_id="O3" value="0.50" spread="4.64"/>
                    <measurement group_id="O4" value="-1.04" spread="6.79"/>
                    <measurement group_id="O5" value="1.02" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.31" spread="8.67"/>
                    <measurement group_id="O2" value="15.83" spread="17.85"/>
                    <measurement group_id="O3" value="9.69" spread="5.13"/>
                    <measurement group_id="O4" value="8.81" spread="14.89"/>
                    <measurement group_id="O5" value="8.04" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="4.29"/>
                    <measurement group_id="O2" value="5.79" spread="36.75"/>
                    <measurement group_id="O3" value="0.81" spread="4.78"/>
                    <measurement group_id="O4" value="-1.45" spread="9.60"/>
                    <measurement group_id="O5" value="0.90" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Accommodation at Week 24: Safety Extension Phase</title>
        <description>The visual accommodation is the distance for each eye at which vision became blurred and was calculated as the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Accommodation at Week 24: Safety Extension Phase</title>
          <description>The visual accommodation is the distance for each eye at which vision became blurred and was calculated as the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately.</description>
          <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Eye: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="5.47"/>
                    <measurement group_id="O2" value="4.33" spread="28.89"/>
                    <measurement group_id="O3" value="1.50" spread="4.80"/>
                    <measurement group_id="O4" value="0.50" spread="4.30"/>
                    <measurement group_id="O5" value="-1.35" spread="13.03"/>
                    <measurement group_id="O6" value="0.96" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Eye: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="5.85"/>
                    <measurement group_id="O2" value="3.79" spread="29.81"/>
                    <measurement group_id="O3" value="1.66" spread="6.25"/>
                    <measurement group_id="O4" value="0.58" spread="4.53"/>
                    <measurement group_id="O5" value="0.43" spread="11.53"/>
                    <measurement group_id="O6" value="1.12" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>CBCL: 120 items questionnaire answered by parent/caregiver of child to assess a child's behavioral, emotional problems. Scale for each item: 0= not true, 1= somewhat/sometimes true, 2= very true/often true. Out of 120 items, 103 were categorized into 8 domains; aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems=anxious/depressed + withdrawn + somatic complaints; Externalizing problems=rule-breaking + aggressive behavior. Total problems=8 domains + other 17 items. Raw scores for each domain, summary and total problems=sum of scores of related items. Using Assessment Data Manager (ADM) tool raw scores transformed/derived into standard T-scores, range: each domain=50 to 100, internalizing problems=34 to 100, externalizing problems=33 to 100, total problems=24 to 100. Lower T-score for each 8 domains, 2 summary and total problems scores=better outcomes.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>CBCL: 120 items questionnaire answered by parent/caregiver of child to assess a child's behavioral, emotional problems. Scale for each item: 0= not true, 1= somewhat/sometimes true, 2= very true/often true. Out of 120 items, 103 were categorized into 8 domains; aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems=anxious/depressed + withdrawn + somatic complaints; Externalizing problems=rule-breaking + aggressive behavior. Total problems=8 domains + other 17 items. Raw scores for each domain, summary and total problems=sum of scores of related items. Using Assessment Data Manager (ADM) tool raw scores transformed/derived into standard T-scores, range: each domain=50 to 100, internalizing problems=34 to 100, externalizing problems=33 to 100, total problems=24 to 100. Lower T-score for each 8 domains, 2 summary and total problems scores=better outcomes.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>T score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aggressive behavior: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.86" spread="5.67"/>
                    <measurement group_id="O2" value="54.32" spread="5.88"/>
                    <measurement group_id="O3" value="54.58" spread="5.75"/>
                    <measurement group_id="O4" value="54.9" spread="5.25"/>
                    <measurement group_id="O5" value="52.8" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggressive behavior: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="3.17"/>
                    <measurement group_id="O2" value="-0.95" spread="3.71"/>
                    <measurement group_id="O3" value="-1.28" spread="2.77"/>
                    <measurement group_id="O4" value="-1.29" spread="3.58"/>
                    <measurement group_id="O5" value="-0.03" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.07" spread="6.99"/>
                    <measurement group_id="O2" value="57.00" spread="8.26"/>
                    <measurement group_id="O3" value="56.75" spread="7.32"/>
                    <measurement group_id="O4" value="55.5" spread="6.58"/>
                    <measurement group_id="O5" value="56.3" spread="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" spread="3.05"/>
                    <measurement group_id="O2" value="-1.38" spread="5.25"/>
                    <measurement group_id="O3" value="-1.92" spread="4.66"/>
                    <measurement group_id="O4" value="-0.79" spread="4.55"/>
                    <measurement group_id="O5" value="-3.21" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.29" spread="5.32"/>
                    <measurement group_id="O2" value="56.66" spread="7.47"/>
                    <measurement group_id="O3" value="56.30" spread="5.68"/>
                    <measurement group_id="O4" value="55.4" spread="5.06"/>
                    <measurement group_id="O5" value="55.3" spread="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems: Change at week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="3.79"/>
                    <measurement group_id="O2" value="-1.40" spread="4.30"/>
                    <measurement group_id="O3" value="-1.28" spread="3.69"/>
                    <measurement group_id="O4" value="-1.29" spread="3.61"/>
                    <measurement group_id="O5" value="-1.45" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.26" spread="3.52"/>
                    <measurement group_id="O2" value="53.80" spread="5.53"/>
                    <measurement group_id="O3" value="53.43" spread="4.96"/>
                    <measurement group_id="O4" value="54.5" spread="4.96"/>
                    <measurement group_id="O5" value="52.3" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="2.99"/>
                    <measurement group_id="O2" value="-0.88" spread="3.91"/>
                    <measurement group_id="O3" value="-0.72" spread="2.76"/>
                    <measurement group_id="O4" value="-1.71" spread="4.84"/>
                    <measurement group_id="O5" value="-0.10" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems : Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.52" spread="5.42"/>
                    <measurement group_id="O2" value="58.54" spread="9.43"/>
                    <measurement group_id="O3" value="57.95" spread="7.90"/>
                    <measurement group_id="O4" value="57.9" spread="6.66"/>
                    <measurement group_id="O5" value="55.8" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems : Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="3.90"/>
                    <measurement group_id="O2" value="-2.55" spread="4.74"/>
                    <measurement group_id="O3" value="-0.67" spread="3.73"/>
                    <measurement group_id="O4" value="-2.21" spread="4.38"/>
                    <measurement group_id="O5" value="-1.10" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.14" spread="6.24"/>
                    <measurement group_id="O2" value="60.46" spread="8.73"/>
                    <measurement group_id="O3" value="60.58" spread="8.44"/>
                    <measurement group_id="O4" value="57.1" spread="6.47"/>
                    <measurement group_id="O5" value="58.4" spread="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="5.99"/>
                    <measurement group_id="O2" value="-1.28" spread="6.35"/>
                    <measurement group_id="O3" value="-0.87" spread="7.16"/>
                    <measurement group_id="O4" value="-0.38" spread="3.97"/>
                    <measurement group_id="O5" value="-1.69" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.00" spread="6.19"/>
                    <measurement group_id="O2" value="53.54" spread="5.93"/>
                    <measurement group_id="O3" value="56.73" spread="7.64"/>
                    <measurement group_id="O4" value="51.9" spread="2.81"/>
                    <measurement group_id="O5" value="54.9" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="4.69"/>
                    <measurement group_id="O2" value="-0.48" spread="4.25"/>
                    <measurement group_id="O3" value="-1.59" spread="3.65"/>
                    <measurement group_id="O4" value="-0.42" spread="1.67"/>
                    <measurement group_id="O5" value="-1.38" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.60" spread="5.17"/>
                    <measurement group_id="O2" value="57.54" spread="8.34"/>
                    <measurement group_id="O3" value="58.25" spread="7.93"/>
                    <measurement group_id="O4" value="55.7" spread="5.96"/>
                    <measurement group_id="O5" value="55.0" spread="7.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="4.70"/>
                    <measurement group_id="O2" value="-1.25" spread="5.13"/>
                    <measurement group_id="O3" value="-1.92" spread="5.08"/>
                    <measurement group_id="O4" value="-1.75" spread="3.97"/>
                    <measurement group_id="O5" value="-0.59" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.48" spread="8.68"/>
                    <measurement group_id="O2" value="49.46" spread="10.00"/>
                    <measurement group_id="O3" value="50.10" spread="9.73"/>
                    <measurement group_id="O4" value="51.1" spread="9.83"/>
                    <measurement group_id="O5" value="48.0" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="5.26"/>
                    <measurement group_id="O2" value="-2.33" spread="5.28"/>
                    <measurement group_id="O3" value="-1.95" spread="4.62"/>
                    <measurement group_id="O4" value="-2.63" spread="4.72"/>
                    <measurement group_id="O5" value="-1.45" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.45" spread="8.06"/>
                    <measurement group_id="O2" value="55.93" spread="12.84"/>
                    <measurement group_id="O3" value="57.25" spread="11.00"/>
                    <measurement group_id="O4" value="53.9" spread="10.34"/>
                    <measurement group_id="O5" value="54.6" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="6.46"/>
                    <measurement group_id="O2" value="-2.35" spread="6.98"/>
                    <measurement group_id="O3" value="-3.05" spread="7.12"/>
                    <measurement group_id="O4" value="-1.96" spread="6.53"/>
                    <measurement group_id="O5" value="-3.52" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Problems: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.05" spread="8.20"/>
                    <measurement group_id="O2" value="53.61" spread="11.98"/>
                    <measurement group_id="O3" value="55.45" spread="10.28"/>
                    <measurement group_id="O4" value="53.4" spread="10.70"/>
                    <measurement group_id="O5" value="52.7" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Problems: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" spread="4.63"/>
                    <measurement group_id="O2" value="-3.23" spread="5.45"/>
                    <measurement group_id="O3" value="-2.36" spread="4.68"/>
                    <measurement group_id="O4" value="-2.17" spread="5.05"/>
                    <measurement group_id="O5" value="-3.38" spread="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 24: Safety Extension Phase</title>
        <description>CBCL: 120 items questionnaire answered by parent/caregiver of child to assess a child's behavioral, emotional problems. Scale for each item: 0= not true, 1= somewhat/sometimes true, 2= very true/often true. Out of 120 items, 103 were categorized into 8 domains; aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems=anxious/depressed + withdrawn + somatic complaints; Externalizing problems=rule-breaking + aggressive behavior. Total problems=8 domains + other 17 items. Raw scores for each domain, summary and total problems=sum of scores of related items. Using Assessment Data Manager (ADM) tool raw scores transformed/derived into standard T-scores, range: each domain=50 to 100, internalizing problems=34 to 100, externalizing problems=33 to 100, total problems=24 to 100. Lower T-score for each 8 domains, 2 summary and total problems scores=better outcomes.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 24: Safety Extension Phase</title>
          <description>CBCL: 120 items questionnaire answered by parent/caregiver of child to assess a child's behavioral, emotional problems. Scale for each item: 0= not true, 1= somewhat/sometimes true, 2= very true/often true. Out of 120 items, 103 were categorized into 8 domains; aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems=anxious/depressed + withdrawn + somatic complaints; Externalizing problems=rule-breaking + aggressive behavior. Total problems=8 domains + other 17 items. Raw scores for each domain, summary and total problems=sum of scores of related items. Using Assessment Data Manager (ADM) tool raw scores transformed/derived into standard T-scores, range: each domain=50 to 100, internalizing problems=34 to 100, externalizing problems=33 to 100, total problems=24 to 100. Lower T-score for each 8 domains, 2 summary and total problems scores=better outcomes.</description>
          <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>T score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aggressive behavior: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="3.85"/>
                    <measurement group_id="O2" value="-1.31" spread="4.57"/>
                    <measurement group_id="O3" value="-1.25" spread="3.40"/>
                    <measurement group_id="O4" value="-2.40" spread="4.89"/>
                    <measurement group_id="O5" value="-1.70" spread="3.40"/>
                    <measurement group_id="O6" value="-1.86" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.45" spread="4.86"/>
                    <measurement group_id="O2" value="-2.31" spread="5.64"/>
                    <measurement group_id="O3" value="-1.50" spread="3.76"/>
                    <measurement group_id="O4" value="-3.25" spread="5.66"/>
                    <measurement group_id="O5" value="-2.60" spread="5.24"/>
                    <measurement group_id="O6" value="-3.89" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="3.99"/>
                    <measurement group_id="O2" value="-2.64" spread="5.72"/>
                    <measurement group_id="O3" value="-3.38" spread="4.65"/>
                    <measurement group_id="O4" value="-1.70" spread="3.01"/>
                    <measurement group_id="O5" value="-1.50" spread="3.15"/>
                    <measurement group_id="O6" value="-1.71" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="3.62"/>
                    <measurement group_id="O2" value="-1.47" spread="5.12"/>
                    <measurement group_id="O3" value="-1.31" spread="4.01"/>
                    <measurement group_id="O4" value="-0.90" spread="2.36"/>
                    <measurement group_id="O5" value="-2.15" spread="3.17"/>
                    <measurement group_id="O6" value="-0.36" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems : Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.83" spread="4.12"/>
                    <measurement group_id="O2" value="-2.56" spread="4.15"/>
                    <measurement group_id="O3" value="-3.19" spread="5.79"/>
                    <measurement group_id="O4" value="-2.65" spread="3.28"/>
                    <measurement group_id="O5" value="-3.90" spread="4.35"/>
                    <measurement group_id="O6" value="-2.36" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.38" spread="6.59"/>
                    <measurement group_id="O2" value="-2.64" spread="6.58"/>
                    <measurement group_id="O3" value="-1.69" spread="9.20"/>
                    <measurement group_id="O4" value="-1.50" spread="5.82"/>
                    <measurement group_id="O5" value="-0.60" spread="3.12"/>
                    <measurement group_id="O6" value="-1.96" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.10" spread="5.45"/>
                    <measurement group_id="O2" value="-1.03" spread="4.52"/>
                    <measurement group_id="O3" value="-3.25" spread="6.62"/>
                    <measurement group_id="O4" value="-2.30" spread="3.50"/>
                    <measurement group_id="O5" value="-1.40" spread="3.00"/>
                    <measurement group_id="O6" value="-1.75" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="4.33"/>
                    <measurement group_id="O2" value="-1.50" spread="5.98"/>
                    <measurement group_id="O3" value="-2.19" spread="3.90"/>
                    <measurement group_id="O4" value="-4.35" spread="5.24"/>
                    <measurement group_id="O5" value="-1.80" spread="5.43"/>
                    <measurement group_id="O6" value="-0.43" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.21" spread="8.20"/>
                    <measurement group_id="O2" value="-2.89" spread="7.06"/>
                    <measurement group_id="O3" value="-1.81" spread="5.42"/>
                    <measurement group_id="O4" value="-4.15" spread="7.44"/>
                    <measurement group_id="O5" value="-4.20" spread="5.15"/>
                    <measurement group_id="O6" value="-4.21" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.69" spread="7.46"/>
                    <measurement group_id="O2" value="-4.14" spread="7.62"/>
                    <measurement group_id="O3" value="-3.25" spread="8.10"/>
                    <measurement group_id="O4" value="-5.35" spread="7.21"/>
                    <measurement group_id="O5" value="-4.40" spread="6.21"/>
                    <measurement group_id="O6" value="-4.32" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Problems: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.03" spread="7.77"/>
                    <measurement group_id="O2" value="-4.44" spread="6.57"/>
                    <measurement group_id="O3" value="-3.69" spread="6.74"/>
                    <measurement group_id="O4" value="-4.90" spread="4.78"/>
                    <measurement group_id="O5" value="-5.20" spread="4.32"/>
                    <measurement group_id="O6" value="-5.25" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Child Behavior Checklist Total Score (Raw Score) at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>CBCL: It consisted of 120 items on behavior and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0= not true, 1= somewhat/sometimes true, 2= very/often true. 103 items were classified in 8 domains: aggressive behavior: total score range (TSR)= 0 to 36, anxious/depressed: TSR= 0 to 26, attention problems: TSR= 0 to 20, rule-breaking behavior: TSR= 0 to 34, social problems: TSR= 0 to 22, somatic complaints: TSR= 0 to 22, thought problems: TSR= 0 to 30, withdrawn (TSR)= 0 to 16. Rule-breaking and aggressive behavior summarized to externalizing problems with a TSR= 0 to 70. Anxious/depressed, withdrawn, somatic complaints summarized to internalizing problems with a TSR= 0 to 64. All 103 items of 8 domains and other 17 remaining items were combined to give total problems TSR = 0 to 240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary and total problems= better outcomes.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Child Behavior Checklist Total Score (Raw Score) at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>CBCL: It consisted of 120 items on behavior and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0= not true, 1= somewhat/sometimes true, 2= very/often true. 103 items were classified in 8 domains: aggressive behavior: total score range (TSR)= 0 to 36, anxious/depressed: TSR= 0 to 26, attention problems: TSR= 0 to 20, rule-breaking behavior: TSR= 0 to 34, social problems: TSR= 0 to 22, somatic complaints: TSR= 0 to 22, thought problems: TSR= 0 to 30, withdrawn (TSR)= 0 to 16. Rule-breaking and aggressive behavior summarized to externalizing problems with a TSR= 0 to 70. Anxious/depressed, withdrawn, somatic complaints summarized to internalizing problems with a TSR= 0 to 64. All 103 items of 8 domains and other 17 remaining items were combined to give total problems TSR = 0 to 240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary and total problems= better outcomes.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Number Analyzed' = participants evaluable for this outcome measure for specified rows.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aggressive behavior: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="4.39"/>
                    <measurement group_id="O2" value="4.66" spread="4.46"/>
                    <measurement group_id="O3" value="4.88" spread="4.35"/>
                    <measurement group_id="O4" value="5.1" spread="3.95"/>
                    <measurement group_id="O5" value="3.5" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggressive behavior: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="2.35"/>
                    <measurement group_id="O2" value="-0.90" spread="2.56"/>
                    <measurement group_id="O3" value="-0.97" spread="2.08"/>
                    <measurement group_id="O4" value="-0.92" spread="2.39"/>
                    <measurement group_id="O5" value="-0.17" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="3.33"/>
                    <measurement group_id="O2" value="4.20" spread="4.06"/>
                    <measurement group_id="O3" value="4.10" spread="3.53"/>
                    <measurement group_id="O4" value="3.8" spread="3.15"/>
                    <measurement group_id="O5" value="4.0" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="1.46"/>
                    <measurement group_id="O2" value="-0.73" spread="2.43"/>
                    <measurement group_id="O3" value="-1.05" spread="2.26"/>
                    <measurement group_id="O4" value="-0.58" spread="2.28"/>
                    <measurement group_id="O5" value="-1.48" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="3.18"/>
                    <measurement group_id="O2" value="4.49" spread="4.11"/>
                    <measurement group_id="O3" value="4.85" spread="3.33"/>
                    <measurement group_id="O4" value="4.2" spread="2.78"/>
                    <measurement group_id="O5" value="3.9" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="2.25"/>
                    <measurement group_id="O2" value="-0.73" spread="2.16"/>
                    <measurement group_id="O3" value="-0.77" spread="2.03"/>
                    <measurement group_id="O4" value="-0.71" spread="1.90"/>
                    <measurement group_id="O5" value="-0.83" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="1.48"/>
                    <measurement group_id="O2" value="1.66" spread="1.98"/>
                    <measurement group_id="O3" value="1.70" spread="1.87"/>
                    <measurement group_id="O4" value="1.9" spread="1.63"/>
                    <measurement group_id="O5" value="1.0" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.09"/>
                    <measurement group_id="O2" value="-0.30" spread="1.36"/>
                    <measurement group_id="O3" value="-0.38" spread="0.99"/>
                    <measurement group_id="O4" value="-0.63" spread="1.56"/>
                    <measurement group_id="O5" value="0.52" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="2.30"/>
                    <measurement group_id="O2" value="4.07" spread="4.12"/>
                    <measurement group_id="O3" value="3.80" spread="3.36"/>
                    <measurement group_id="O4" value="3.9" spread="2.99"/>
                    <measurement group_id="O5" value="3.2" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="1.54"/>
                    <measurement group_id="O2" value="-1.13" spread="2.09"/>
                    <measurement group_id="O3" value="-0.26" spread="1.57"/>
                    <measurement group_id="O4" value="-0.83" spread="1.86"/>
                    <measurement group_id="O5" value="-0.62" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="2.18"/>
                    <measurement group_id="O2" value="3.46" spread="3.26"/>
                    <measurement group_id="O3" value="3.40" spread="3.23"/>
                    <measurement group_id="O4" value="2.1" spread="1.93"/>
                    <measurement group_id="O5" value="2.6" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="2.26"/>
                    <measurement group_id="O2" value="-0.53" spread="2.44"/>
                    <measurement group_id="O3" value="-0.51" spread="2.64"/>
                    <measurement group_id="O4" value="-0.04" spread="1.55"/>
                    <measurement group_id="O5" value="-0.55" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="2.23"/>
                    <measurement group_id="O2" value="1.46" spread="2.34"/>
                    <measurement group_id="O3" value="2.58" spread="2.92"/>
                    <measurement group_id="O4" value="1.0" spread="1.04"/>
                    <measurement group_id="O5" value="2.0" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="1.69"/>
                    <measurement group_id="O2" value="-0.10" spread="1.37"/>
                    <measurement group_id="O3" value="-0.51" spread="1.30"/>
                    <measurement group_id="O4" value="-0.21" spread="0.72"/>
                    <measurement group_id="O5" value="-0.45" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="1.77"/>
                    <measurement group_id="O2" value="2.49" spread="2.78"/>
                    <measurement group_id="O3" value="2.75" spread="2.66"/>
                    <measurement group_id="O4" value="1.7" spread="1.81"/>
                    <measurement group_id="O5" value="1.6" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="1.44"/>
                    <measurement group_id="O2" value="-0.35" spread="1.59"/>
                    <measurement group_id="O3" value="-0.64" spread="1.77"/>
                    <measurement group_id="O4" value="-0.50" spread="1.10"/>
                    <measurement group_id="O5" value="-0.17" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="5.23"/>
                    <measurement group_id="O2" value="6.32" spread="6.14"/>
                    <measurement group_id="O3" value="6.53" spread="5.87"/>
                    <measurement group_id="O4" value="6.9" spread="5.16"/>
                    <measurement group_id="O5" value="4.5" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="2.85"/>
                    <measurement group_id="O2" value="-1.20" spread="3.42"/>
                    <measurement group_id="O3" value="-1.31" spread="2.30"/>
                    <measurement group_id="O4" value="-1.54" spread="3.50"/>
                    <measurement group_id="O5" value="-0.31" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.76" spread="5.56"/>
                    <measurement group_id="O2" value="10.15" spread="8.64"/>
                    <measurement group_id="O3" value="10.25" spread="7.02"/>
                    <measurement group_id="O4" value="7.5" spread="5.61"/>
                    <measurement group_id="O5" value="8.2" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="3.62"/>
                    <measurement group_id="O2" value="-1.70" spread="5.16"/>
                    <measurement group_id="O3" value="-2.21" spread="4.35"/>
                    <measurement group_id="O4" value="-1.13" spread="3.85"/>
                    <measurement group_id="O5" value="-2.21" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Problems: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.52" spread="16.84"/>
                    <measurement group_id="O2" value="31.88" spread="23.78"/>
                    <measurement group_id="O3" value="34.18" spread="22.16"/>
                    <measurement group_id="O4" value="29.5" spread="17.41"/>
                    <measurement group_id="O5" value="27.0" spread="16.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Problems: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.92" spread="8.73"/>
                    <measurement group_id="O2" value="-5.83" spread="12.16"/>
                    <measurement group_id="O3" value="-5.85" spread="9.77"/>
                    <measurement group_id="O4" value="-5.33" spread="8.29"/>
                    <measurement group_id="O5" value="-5.10" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Child Behavior Checklist Total Score (Raw Score) at Week 24: Safety Extension Phase</title>
        <description>CBCL: It consisted of 120 items on behavior and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0= not true, 1= somewhat/sometimes true, 2= very/often true. 103 items were classified in 8 domains: aggressive behavior: total score range (TSR)= 0 to 36, anxious/depressed: TSR= 0 to 26, attention problems: TSR= 0 to 20, rule-breaking behavior: TSR= 0 to 34, social problems: TSR= 0 to 22, somatic complaints: TSR= 0 to 22, thought problems: TSR= 0 to 30, withdrawn (TSR)= 0 to 16. Rule-breaking and aggressive behavior summarized to externalizing problems with a TSR= 0 to 70. Anxious/depressed, withdrawn, somatic complaints summarized to internalizing problems with a TSR= 0 to 64. All 103 items of 8 domains and other 17 remaining items were combined to give total problems TSR = 0 to 240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary and total problems= better outcomes.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for safety extension phase: all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Child Behavior Checklist Total Score (Raw Score) at Week 24: Safety Extension Phase</title>
          <description>CBCL: It consisted of 120 items on behavior and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0= not true, 1= somewhat/sometimes true, 2= very/often true. 103 items were classified in 8 domains: aggressive behavior: total score range (TSR)= 0 to 36, anxious/depressed: TSR= 0 to 26, attention problems: TSR= 0 to 20, rule-breaking behavior: TSR= 0 to 34, social problems: TSR= 0 to 22, somatic complaints: TSR= 0 to 22, thought problems: TSR= 0 to 30, withdrawn (TSR)= 0 to 16. Rule-breaking and aggressive behavior summarized to externalizing problems with a TSR= 0 to 70. Anxious/depressed, withdrawn, somatic complaints summarized to internalizing problems with a TSR= 0 to 64. All 103 items of 8 domains and other 17 remaining items were combined to give total problems TSR = 0 to 240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary and total problems= better outcomes.</description>
          <population>Safety analysis set population for safety extension phase: all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aggressive behavior: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="2.92"/>
                    <measurement group_id="O2" value="-1.17" spread="3.10"/>
                    <measurement group_id="O3" value="-0.81" spread="2.43"/>
                    <measurement group_id="O4" value="-1.75" spread="3.58"/>
                    <measurement group_id="O5" value="-1.40" spread="2.41"/>
                    <measurement group_id="O6" value="-1.57" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious/depressed: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="2.22"/>
                    <measurement group_id="O2" value="-1.28" spread="2.42"/>
                    <measurement group_id="O3" value="-1.06" spread="1.88"/>
                    <measurement group_id="O4" value="-1.60" spread="2.48"/>
                    <measurement group_id="O5" value="-1.70" spread="2.36"/>
                    <measurement group_id="O6" value="-1.75" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention problems: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="2.31"/>
                    <measurement group_id="O2" value="-1.36" spread="2.77"/>
                    <measurement group_id="O3" value="-1.94" spread="2.35"/>
                    <measurement group_id="O4" value="-1.25" spread="1.77"/>
                    <measurement group_id="O5" value="-1.15" spread="1.76"/>
                    <measurement group_id="O6" value="-0.89" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rule-breaking behavior: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="1.29"/>
                    <measurement group_id="O2" value="-0.50" spread="1.65"/>
                    <measurement group_id="O3" value="-0.50" spread="1.21"/>
                    <measurement group_id="O4" value="-0.55" spread="0.94"/>
                    <measurement group_id="O5" value="-0.80" spread="1.01"/>
                    <measurement group_id="O6" value="-0.18" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social problems: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="1.53"/>
                    <measurement group_id="O2" value="-1.19" spread="1.97"/>
                    <measurement group_id="O3" value="-1.13" spread="2.33"/>
                    <measurement group_id="O4" value="-1.20" spread="1.36"/>
                    <measurement group_id="O5" value="-1.65" spread="1.81"/>
                    <measurement group_id="O6" value="-1.14" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic complaints: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="2.22"/>
                    <measurement group_id="O2" value="-0.89" spread="2.38"/>
                    <measurement group_id="O3" value="-0.88" spread="3.32"/>
                    <measurement group_id="O4" value="-0.45" spread="1.73"/>
                    <measurement group_id="O5" value="-0.15" spread="0.88"/>
                    <measurement group_id="O6" value="-0.68" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thought problems: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.95"/>
                    <measurement group_id="O2" value="-0.36" spread="1.40"/>
                    <measurement group_id="O3" value="-1.06" spread="2.14"/>
                    <measurement group_id="O4" value="-0.90" spread="1.21"/>
                    <measurement group_id="O5" value="-0.65" spread="1.04"/>
                    <measurement group_id="O6" value="-0.64" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawn: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="1.43"/>
                    <measurement group_id="O2" value="-0.44" spread="2.01"/>
                    <measurement group_id="O3" value="-0.69" spread="1.35"/>
                    <measurement group_id="O4" value="-1.35" spread="1.66"/>
                    <measurement group_id="O5" value="-0.45" spread="1.50"/>
                    <measurement group_id="O6" value="-0.14" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Externalizing: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="3.50"/>
                    <measurement group_id="O2" value="-1.67" spread="4.27"/>
                    <measurement group_id="O3" value="-1.19" spread="3.23"/>
                    <measurement group_id="O4" value="-2.30" spread="4.03"/>
                    <measurement group_id="O5" value="-2.20" spread="2.84"/>
                    <measurement group_id="O6" value="-1.79" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internalizing: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.52" spread="4.00"/>
                    <measurement group_id="O2" value="-2.61" spread="4.95"/>
                    <measurement group_id="O3" value="-2.63" spread="4.65"/>
                    <measurement group_id="O4" value="-3.40" spread="4.68"/>
                    <measurement group_id="O5" value="-2.30" spread="3.64"/>
                    <measurement group_id="O6" value="-2.57" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Problems: Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.90" spread="11.98"/>
                    <measurement group_id="O2" value="-8.58" spread="12.86"/>
                    <measurement group_id="O3" value="-9.00" spread="13.45"/>
                    <measurement group_id="O4" value="-10.10" spread="10.47"/>
                    <measurement group_id="O5" value="-9.45" spread="7.93"/>
                    <measurement group_id="O6" value="-8.39" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.11" spread="31.66"/>
                    <measurement group_id="O2" value="56.50" spread="32.09"/>
                    <measurement group_id="O3" value="46.43" spread="16.28"/>
                    <measurement group_id="O4" value="69.56" spread="58.52"/>
                    <measurement group_id="O5" value="52.20" spread="31.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.71" spread="11.06"/>
                    <measurement group_id="O2" value="10.14" spread="37.18"/>
                    <measurement group_id="O3" value="-5.33" spread="6.15"/>
                    <measurement group_id="O4" value="-11.20" spread="41.11"/>
                    <measurement group_id="O5" value="-10.26" spread="27.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.44" spread="41.45"/>
                    <measurement group_id="O2" value="114.00" spread="89.43"/>
                    <measurement group_id="O3" value="48.00" spread="15.14"/>
                    <measurement group_id="O4" value="91.29" spread="110.76"/>
                    <measurement group_id="O5" value="76.29" spread="76.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.71" spread="25.44"/>
                    <measurement group_id="O2" value="15.33" spread="49.28"/>
                    <measurement group_id="O3" value="-2.00" spread="12.25"/>
                    <measurement group_id="O4" value="-19.36" spread="81.03"/>
                    <measurement group_id="O5" value="-3.25" spread="22.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.33" spread="9.07"/>
                    <measurement group_id="O2" value="-3.71" spread="22.94"/>
                    <measurement group_id="O3" value="-2.00" spread="8.49"/>
                    <measurement group_id="O4" value="-6.33" spread="3.06"/>
                    <measurement group_id="O5" value="-7.07" spread="6.80"/>
                    <measurement group_id="O6" value="-15.00" spread="28.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="13.75"/>
                    <measurement group_id="O2" value="-4.00" spread="29.09"/>
                    <measurement group_id="O3" value="1.50" spread="10.61"/>
                    <measurement group_id="O4" value="-11.00" spread="5.00"/>
                    <measurement group_id="O5" value="-9.14" spread="14.33"/>
                    <measurement group_id="O6" value="-18.47" spread="38.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.85" spread="24.22"/>
                    <measurement group_id="O2" value="92.15" spread="40.51"/>
                    <measurement group_id="O3" value="82.64" spread="24.32"/>
                    <measurement group_id="O4" value="106.7" spread="64.07"/>
                    <measurement group_id="O5" value="124.7" spread="71.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.40" spread="10.43"/>
                    <measurement group_id="O2" value="-8.88" spread="20.76"/>
                    <measurement group_id="O3" value="1.21" spread="11.87"/>
                    <measurement group_id="O4" value="-14.38" spread="25.90"/>
                    <measurement group_id="O5" value="-18.44" spread="32.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.61" spread="59.63"/>
                    <measurement group_id="O2" value="109.00" spread="49.75"/>
                    <measurement group_id="O3" value="92.94" spread="25.05"/>
                    <measurement group_id="O4" value="130.30" spread="83.58"/>
                    <measurement group_id="O5" value="126.1" spread="48.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.10" spread="19.94"/>
                    <measurement group_id="O2" value="-4.10" spread="10.79"/>
                    <measurement group_id="O3" value="-1.97" spread="14.00"/>
                    <measurement group_id="O4" value="-13.50" spread="18.81"/>
                    <measurement group_id="O5" value="-12.50" spread="20.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 25-peg assessment was done only in participants of age 9 years and above. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 25-peg assessment was done only in participants of age 9 years and above. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.20" spread="11.67"/>
                    <measurement group_id="O2" value="-12.27" spread="18.28"/>
                    <measurement group_id="O3" value="-5.71" spread="9.55"/>
                    <measurement group_id="O4" value="-7.00" spread="13.25"/>
                    <measurement group_id="O5" value="-38.20" spread="31.67"/>
                    <measurement group_id="O6" value="-17.00" spread="33.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.24" spread="15.79"/>
                    <measurement group_id="O2" value="-8.46" spread="10.42"/>
                    <measurement group_id="O3" value="-3.79" spread="11.89"/>
                    <measurement group_id="O4" value="-11.87" spread="14.15"/>
                    <measurement group_id="O5" value="-38.00" spread="29.35"/>
                    <measurement group_id="O6" value="-15.50" spread="29.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.33"/>
                    <measurement group_id="O2" value="0.75" spread="1.75"/>
                    <measurement group_id="O3" value="0.29" spread="0.49"/>
                    <measurement group_id="O4" value="0.39" spread="1.24"/>
                    <measurement group_id="O5" value="0.10" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.76"/>
                    <measurement group_id="O2" value="0.57" spread="1.13"/>
                    <measurement group_id="O3" value="-0.17" spread="0.75"/>
                    <measurement group_id="O4" value="0.00" spread="1.77"/>
                    <measurement group_id="O5" value="0.05" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.53"/>
                    <measurement group_id="O2" value="1.22" spread="2.28"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.35" spread="0.86"/>
                    <measurement group_id="O5" value="0.76" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="1.27"/>
                    <measurement group_id="O2" value="1.00" spread="2.00"/>
                    <measurement group_id="O3" value="0.17" spread="0.41"/>
                    <measurement group_id="O4" value="0.00" spread="0.68"/>
                    <measurement group_id="O5" value="0.60" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1,SEP: Oxybutynin Then Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin 5 mg ER tablets orally once daily in active comparator phase, were allocated by investigator to receive fesoterodine 8 mg for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Change at week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.58"/>
                    <measurement group_id="O2" value="0.43" spread="0.79"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="-0.33" spread="0.58"/>
                    <measurement group_id="O5" value="-0.27" spread="1.39"/>
                    <measurement group_id="O6" value="-0.06" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="2.31"/>
                    <measurement group_id="O2" value="0.00" spread="1.10"/>
                    <measurement group_id="O3" value="0.50" spread="0.71"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="-0.36" spread="0.74"/>
                    <measurement group_id="O6" value="0.11" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="1.20"/>
                    <measurement group_id="O2" value="0.24" spread="0.50"/>
                    <measurement group_id="O3" value="0.24" spread="0.66"/>
                    <measurement group_id="O4" value="0.10" spread="0.32"/>
                    <measurement group_id="O5" value="0.11" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="1.05"/>
                    <measurement group_id="O2" value="-0.18" spread="0.58"/>
                    <measurement group_id="O3" value="0.09" spread="0.77"/>
                    <measurement group_id="O4" value="0.00" spread="0.53"/>
                    <measurement group_id="O5" value="0.44" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="2.36"/>
                    <measurement group_id="O2" value="0.28" spread="0.46"/>
                    <measurement group_id="O3" value="0.36" spread="0.78"/>
                    <measurement group_id="O4" value="0.40" spread="0.97"/>
                    <measurement group_id="O5" value="0.13" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="1.60"/>
                    <measurement group_id="O2" value="0.06" spread="1.03"/>
                    <measurement group_id="O3" value="0.21" spread="1.78"/>
                    <measurement group_id="O4" value="0.13" spread="0.35"/>
                    <measurement group_id="O5" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 25-peg assessment was done only in participants of age 9 years and above. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 25-peg assessment was done only in participants of age 9 years and above. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.87"/>
                    <measurement group_id="O2" value="0.63" spread="4.63"/>
                    <measurement group_id="O3" value="0.14" spread="0.36"/>
                    <measurement group_id="O4" value="0.25" spread="1.24"/>
                    <measurement group_id="O5" value="0.00" spread="0.00"/>
                    <measurement group_id="O6" value="0.44" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="2.17"/>
                    <measurement group_id="O2" value="0.68" spread="4.79"/>
                    <measurement group_id="O3" value="0.00" spread="0.39"/>
                    <measurement group_id="O4" value="0.27" spread="1.67"/>
                    <measurement group_id="O5" value="0.60" spread="0.89"/>
                    <measurement group_id="O6" value="-0.13" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" spread="1.01"/>
                    <measurement group_id="O2" value="9.38" spread="1.77"/>
                    <measurement group_id="O3" value="10.00" spread="0.00"/>
                    <measurement group_id="O4" value="9.89" spread="0.47"/>
                    <measurement group_id="O5" value="10.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.76"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.38"/>
                    <measurement group_id="O5" value="-0.11" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" spread="1.01"/>
                    <measurement group_id="O2" value="9.00" spread="2.35"/>
                    <measurement group_id="O3" value="10.00" spread="0.00"/>
                    <measurement group_id="O4" value="9.82" spread="0.73"/>
                    <measurement group_id="O5" value="9.62" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="1.13"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="-0.07" spread="0.62"/>
                    <measurement group_id="O5" value="0.00" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.58"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.07" spread="0.26"/>
                    <measurement group_id="O6" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="2.31"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.14" spread="0.53"/>
                    <measurement group_id="O6" value="0.21" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 10-peg assessment was done only in participants below age of 9 years. &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure, &quot;Number Analyzed&quot;: participants evaluable for specified rows. There was 1 participant who inadvertently did the 10-peg test with non-dominant hand and 25-peg test with dominant hand. This participant was counted in both 10 peg and 25 peg assessment.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" spread="0.00"/>
                    <measurement group_id="O2" value="24.56" spread="1.89"/>
                    <measurement group_id="O3" value="25.00" spread="0.00"/>
                    <measurement group_id="O4" value="25.00" spread="0.00"/>
                    <measurement group_id="O5" value="23.22" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.25"/>
                    <measurement group_id="O2" value="0.42" spread="1.77"/>
                    <measurement group_id="O3" value="-0.12" spread="0.70"/>
                    <measurement group_id="O4" value="-0.13" spread="0.35"/>
                    <measurement group_id="O5" value="0.11" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.45" spread="2.09"/>
                    <measurement group_id="O2" value="24.75" spread="0.92"/>
                    <measurement group_id="O3" value="24.88" spread="0.42"/>
                    <measurement group_id="O4" value="24.50" spread="1.58"/>
                    <measurement group_id="O5" value="24.25" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="2.19"/>
                    <measurement group_id="O2" value="0.26" spread="0.93"/>
                    <measurement group_id="O3" value="0.03" spread="0.30"/>
                    <measurement group_id="O4" value="0.63" spread="1.77"/>
                    <measurement group_id="O5" value="-0.63" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase</title>
        <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 25-peg assessment was done only in participants of age 9 years and above. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase</title>
          <description>The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase analyzed. 25-peg assessment was done only in participants of age 9 years and above. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure and &quot;Number Analyzed&quot;: participants evaluable for specified rows.</population>
          <units>pegs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dominant hand: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.50" spread="2.01"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.00" spread="0.00"/>
                    <measurement group_id="O6" value="0.11" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-dominant hand: Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="2.40"/>
                    <measurement group_id="O2" value="0.21" spread="0.96"/>
                    <measurement group_id="O3" value="0.14" spread="0.66"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.60" spread="2.61"/>
                    <measurement group_id="O6" value="-0.50" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting Pre-defined Criteria for Vital Signs Values From Baseline Through Week 12: Active Comparator/Efficacy Phase</title>
        <description>Pre-defined criteria for vital signs: 1) a) systolic blood pressure (SBP) of &lt;90 millimeter of mercury (mmHg), b) change &gt;=30 mmHg increase, c) change &gt;=30 mmHg decrease; 2) a) diastolic blood pressure (DBP) of &lt;50 mmHg, b) change &gt;=20 mmHg increase, c) change &gt;=20 mmHg decrease; 3) a) pulse rate value of &lt;40 beats per minute (bpm), b) pulse rate value &gt;120 bpm.</description>
        <time_frame>Baseline up to Week 12</time_frame>
        <population>Analysis set population for active comparator phase and efficacy phase: all participants of respective cohorts who received at least 1 dose of study medication in relevant phase. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting Pre-defined Criteria for Vital Signs Values From Baseline Through Week 12: Active Comparator/Efficacy Phase</title>
          <description>Pre-defined criteria for vital signs: 1) a) systolic blood pressure (SBP) of &lt;90 millimeter of mercury (mmHg), b) change &gt;=30 mmHg increase, c) change &gt;=30 mmHg decrease; 2) a) diastolic blood pressure (DBP) of &lt;50 mmHg, b) change &gt;=20 mmHg increase, c) change &gt;=20 mmHg decrease; 3) a) pulse rate value of &lt;40 beats per minute (bpm), b) pulse rate value &gt;120 bpm.</description>
          <population>Analysis set population for active comparator phase and efficacy phase: all participants of respective cohorts who received at least 1 dose of study medication in relevant phase. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP: &lt;90 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Change &gt;=30 mmHg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Change &gt;=30 mmHg decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Change &gt;=20 mmHg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Change &gt;=20 mmHg decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate: &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate: &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting Pre-defined Criteria for Vital Signs Values From Baseline Through Week 24: Safety Extension Phase</title>
        <description>Pre-defined criteria for vital signs: 1) a) systolic blood pressure (SBP) of &lt;90 millimeter of mercury (mmHg), b) change &gt;=30 mmHg increase, c) change &gt;=30 mmHg decrease; 2) a) diastolic blood pressure (DBP) of &lt;50 mmHg, b) change &gt;=20 mmHg increase, c) change &gt;=20 mmHg decrease; 3) a) pulse rate value of &lt;40 beats per minute (bpm), b) pulse rate value &gt;120 bpm.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting Pre-defined Criteria for Vital Signs Values From Baseline Through Week 24: Safety Extension Phase</title>
          <description>Pre-defined criteria for vital signs: 1) a) systolic blood pressure (SBP) of &lt;90 millimeter of mercury (mmHg), b) change &gt;=30 mmHg increase, c) change &gt;=30 mmHg decrease; 2) a) diastolic blood pressure (DBP) of &lt;50 mmHg, b) change &gt;=20 mmHg increase, c) change &gt;=20 mmHg decrease; 3) a) pulse rate value of &lt;40 beats per minute (bpm), b) pulse rate value &gt;120 bpm.</description>
          <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP: &lt;90 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Change &gt;=30 mmHg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Change &gt;=30 mmHg decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Change &gt;=20 mmHg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Change &gt;=20 mmHg decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate: &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate: &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Urinary Tract Infections (UTI): Active Comparator/Efficacy Phase</title>
        <description>Clinically significant UTI, counted as an adverse event was defined as: positive urine culture with a uropathogen (defined as &gt;=10^5 colony forming unit per milliliter [CFU/mL]) and the presence of symptoms, or pyuria (defined as &gt;50 white blood cells [WBC] per high-pass filter [hpf]) and the presence of symptoms, or positive urine culture with a uropathogen (defined as &gt;=10^5 CFU/mL) with or without symptoms in a participant with a documented history of vesicoureteral reflux (VUR).</description>
        <time_frame>Week 1 up to Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase: all participants of respective cohorts who received at least 1 dose of study medication in relevant phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Urinary Tract Infections (UTI): Active Comparator/Efficacy Phase</title>
          <description>Clinically significant UTI, counted as an adverse event was defined as: positive urine culture with a uropathogen (defined as &gt;=10^5 colony forming unit per milliliter [CFU/mL]) and the presence of symptoms, or pyuria (defined as &gt;50 white blood cells [WBC] per high-pass filter [hpf]) and the presence of symptoms, or positive urine culture with a uropathogen (defined as &gt;=10^5 CFU/mL) with or without symptoms in a participant with a documented history of vesicoureteral reflux (VUR).</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase: all participants of respective cohorts who received at least 1 dose of study medication in relevant phase of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Urinary Tract Infections (UTI): Safety Extension Phase</title>
        <description>Clinically significant UTI, counted as an adverse event was defined as: positive urine culture with a uropathogen (defined as &gt;=10^5 CFU/mL) and the presence of symptoms, or pyuria (defined as &gt;50 WBC per hpf and the presence of symptoms, or positive urine culture with a uropathogen (defined as &gt;=10^5 CFU/mL) with or without symptoms in a participants with a documented history of VUR.</description>
        <time_frame>Week 12 up to Week 26</time_frame>
        <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Urinary Tract Infections (UTI): Safety Extension Phase</title>
          <description>Clinically significant UTI, counted as an adverse event was defined as: positive urine culture with a uropathogen (defined as &gt;=10^5 CFU/mL) and the presence of symptoms, or pyuria (defined as &gt;50 WBC per hpf and the presence of symptoms, or positive urine culture with a uropathogen (defined as &gt;=10^5 CFU/mL) with or without symptoms in a participants with a documented history of VUR.</description>
          <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Laboratory Abnormalities: Active Comparator/Efficacy Phase</title>
        <description>Hematology: hemoglobin, hematocrit, erythrocytes &lt;0.8*lower limit of normal (LLN), platelets&lt;0.5*LLN&gt;1.75*upper limit of normal (ULN), leukocytes &lt;0.6*LLN&gt;1.5*ULN, lymphocytes, neutrophils, &lt;0.8*LLN &gt;1.2*ULN, basophils, eosinophils, monocytes monocytes/leukocytes &gt;1.2*ULN. Clinical chemistry: bilirubin, direct, bilirubin &gt;1.5*ULN, aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase&gt;3.0*ULN, protein, albumin, phosphate &lt;0.8*LLN &gt;1.2*ULN, blood urea nitrogen, creatinine &gt;1.3*ULN, urate &gt;1.2*ULN, sodium&lt;0.95*LLN&gt;1.05*ULN, potassium, chloride, calcium bicarbonate&lt;0.9*LLN&gt;1.1*ULN, glucose&lt;0.6*LLN&gt;1.5*ULN, creatine kinase &gt;2.0*ULN. Urinalysis: specific gravity &lt;1.003&gt;1.030, pH &lt;4.5&gt;8, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite, &gt;=1, urine erythrocytes, urine leukocytes &gt;=20, epithelial cells &gt;=6, bacteria &gt;20.</description>
        <time_frame>Week 1 up to Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase: all participants of respective cohorts who received at least 1 dose of study medication in relevant phase. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Laboratory Abnormalities: Active Comparator/Efficacy Phase</title>
          <description>Hematology: hemoglobin, hematocrit, erythrocytes &lt;0.8*lower limit of normal (LLN), platelets&lt;0.5*LLN&gt;1.75*upper limit of normal (ULN), leukocytes &lt;0.6*LLN&gt;1.5*ULN, lymphocytes, neutrophils, &lt;0.8*LLN &gt;1.2*ULN, basophils, eosinophils, monocytes monocytes/leukocytes &gt;1.2*ULN. Clinical chemistry: bilirubin, direct, bilirubin &gt;1.5*ULN, aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase&gt;3.0*ULN, protein, albumin, phosphate &lt;0.8*LLN &gt;1.2*ULN, blood urea nitrogen, creatinine &gt;1.3*ULN, urate &gt;1.2*ULN, sodium&lt;0.95*LLN&gt;1.05*ULN, potassium, chloride, calcium bicarbonate&lt;0.9*LLN&gt;1.1*ULN, glucose&lt;0.6*LLN&gt;1.5*ULN, creatine kinase &gt;2.0*ULN. Urinalysis: specific gravity &lt;1.003&gt;1.030, pH &lt;4.5&gt;8, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite, &gt;=1, urine erythrocytes, urine leukocytes &gt;=20, epithelial cells &gt;=6, bacteria &gt;20.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase: all participants of respective cohorts who received at least 1 dose of study medication in relevant phase. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Laboratory Abnormalities: Safety Extension Phase</title>
        <description>Hematology: hemoglobin, hematocrit, erythrocytes &lt;0.8*lower limit of normal (LLN), platelets&lt;0.5*LLN&gt;1.75*upper limit of normal (ULN), leukocytes &lt;0.6*LLN&gt;1.5*ULN, lymphocytes, neutrophils, &lt;0.8*LLN &gt;1.2*ULN, basophils, eosinophils, monocytes monocytes/leukocytes &gt;1.2*ULN. Clinical chemistry: bilirubin, direct, bilirubin &gt;1.5*ULN, aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase&gt;3.0*ULN, protein, albumin, phosphate &lt;0.8*LLN &gt;1.2*ULN, blood urea nitrogen, creatinine &gt;1.3*ULN, urate &gt;1.2*ULN, sodium&lt;0.95*LLN&gt;1.05*ULN, potassium, chloride, calcium bicarbonate&lt;0.9*LLN&gt;1.1*ULN, glucose&lt;0.6*LLN&gt;1.5*ULN, creatine kinase &gt;2.0*ULN. Urinalysis: specific gravity &lt;1.003&gt;1.030, pH &lt;4.5&gt;8, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite, &gt;=1, urine erythrocytes, urine leukocytes &gt;=20, epithelial cells &gt;=6, bacteria &gt;20.</description>
        <time_frame>Week 12 up to Week 26</time_frame>
        <population>Safety analysis set population for safety extension phase: all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Laboratory Abnormalities: Safety Extension Phase</title>
          <description>Hematology: hemoglobin, hematocrit, erythrocytes &lt;0.8*lower limit of normal (LLN), platelets&lt;0.5*LLN&gt;1.75*upper limit of normal (ULN), leukocytes &lt;0.6*LLN&gt;1.5*ULN, lymphocytes, neutrophils, &lt;0.8*LLN &gt;1.2*ULN, basophils, eosinophils, monocytes monocytes/leukocytes &gt;1.2*ULN. Clinical chemistry: bilirubin, direct, bilirubin &gt;1.5*ULN, aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase&gt;3.0*ULN, protein, albumin, phosphate &lt;0.8*LLN &gt;1.2*ULN, blood urea nitrogen, creatinine &gt;1.3*ULN, urate &gt;1.2*ULN, sodium&lt;0.95*LLN&gt;1.05*ULN, potassium, chloride, calcium bicarbonate&lt;0.9*LLN&gt;1.1*ULN, glucose&lt;0.6*LLN&gt;1.5*ULN, creatine kinase &gt;2.0*ULN. Urinalysis: specific gravity &lt;1.003&gt;1.030, pH &lt;4.5&gt;8, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite, &gt;=1, urine erythrocytes, urine leukocytes &gt;=20, epithelial cells &gt;=6, bacteria &gt;20.</description>
          <population>Safety analysis set population for safety extension phase: all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-Void Residual (PVR) Volume at Weeks 4, 12: Active Comparator Phase/Efficacy Phase</title>
        <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study.</description>
        <time_frame>Baseline, Week 4, 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase: all participants of respective cohorts who received at least 1 dose of study medication in relevant phase. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure; &quot;Number Analyzed&quot;: participants evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Void Residual (PVR) Volume at Weeks 4, 12: Active Comparator Phase/Efficacy Phase</title>
          <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase: all participants of respective cohorts who received at least 1 dose of study medication in relevant phase. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure; &quot;Number Analyzed&quot;: participants evaluable at specified time points.</population>
          <units>milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" spread="8.20"/>
                    <measurement group_id="O2" value="9.57" spread="12.54"/>
                    <measurement group_id="O3" value="5.78" spread="7.98"/>
                    <measurement group_id="O4" value="14.7" spread="14.31"/>
                    <measurement group_id="O5" value="10.7" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.40" spread="7.60"/>
                    <measurement group_id="O2" value="-7.33" spread="10.88"/>
                    <measurement group_id="O3" value="19.11" spread="24.52"/>
                    <measurement group_id="O4" value="-2.00" spread="6.24"/>
                    <measurement group_id="O5" value="10.25" spread="34.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.60" spread="53.42"/>
                    <measurement group_id="O2" value="-4.00" spread="8.41"/>
                    <measurement group_id="O3" value="12.86" spread="43.48"/>
                    <measurement group_id="O4" value="2.50" spread="16.05"/>
                    <measurement group_id="O5" value="0.75" spread="17.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-Void Residual Volume at Week 24: Safety Extension Phase</title>
        <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Safety analysis set population for safety extension phase: all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Void Residual Volume at Week 24: Safety Extension Phase</title>
          <description>Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had &gt;1 UTI during the study.</description>
          <population>Safety analysis set population for safety extension phase: all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure.</population>
          <units>milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.50" spread="23.67"/>
                    <measurement group_id="O2" value="11.60" spread="29.43"/>
                    <measurement group_id="O3" value="18.00" spread="31.36"/>
                    <measurement group_id="O4" value="36.67" spread="59.23"/>
                    <measurement group_id="O5" value="21.67" spread="20.21"/>
                    <measurement group_id="O6" value="2.75" spread="14.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Changes in Physical Examination Findings From Baseline to Week 12: Active Comparator/Efficacy Phase</title>
        <description>Physical examination included assessment of the general appearance and the skin, head, ears, eyes, nose, mouth, throat, respiratory, cardiovascular, gastrointestinal, musculoskeletal and neurological systems. Clinically relevant changes in physical findings were assessed by the investigator.</description>
        <time_frame>Baseline up to Week 12</time_frame>
        <population>Safety analysis set population for active comparator phase and efficacy phase: all participants of respective cohorts who received at least 1 dose of study medication in relevant phase of the study. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
            <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg Then 4 mg</title>
            <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Changes in Physical Examination Findings From Baseline to Week 12: Active Comparator/Efficacy Phase</title>
          <description>Physical examination included assessment of the general appearance and the skin, head, ears, eyes, nose, mouth, throat, respiratory, cardiovascular, gastrointestinal, musculoskeletal and neurological systems. Clinically relevant changes in physical findings were assessed by the investigator.</description>
          <population>Safety analysis set population for active comparator phase and efficacy phase: all participants of respective cohorts who received at least 1 dose of study medication in relevant phase of the study. Here, &quot;Overall Number of Participants Analyzed&quot;: participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Changes in Physical Examination Findings From Baseline to Week 24: Safety Extension Phase</title>
        <description>Physical examination included assessment of the general appearance and the skin, head, ears, eyes, nose, mouth, throat, respiratory, cardiovascular, gastrointestinal, musculoskeletal and neurological systems. Clinically relevant changes in physical findings were assessed by the investigator.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Safety Extension Phase: Fesoterodine 8 mg</title>
            <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg Then 8 mg</title>
            <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
            <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Changes in Physical Examination Findings From Baseline to Week 24: Safety Extension Phase</title>
          <description>Physical examination included assessment of the general appearance and the skin, head, ears, eyes, nose, mouth, throat, respiratory, cardiovascular, gastrointestinal, musculoskeletal and neurological systems. Clinically relevant changes in physical findings were assessed by the investigator.</description>
          <population>Safety analysis set population for safety extension phase included all participants of respective cohorts who received at least 1 dose of study medication in the relevant phase of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absorption Rate Constant (Ka) of Fesoterodine</title>
        <description>Absorption rate constant is used to determine rate at which drug is entering into body. Pharmacokinetic (PK) analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.</description>
        <time_frame>Week 4, Day 1: pre-dose (when dose administered at clinic) or if dose taken at home up to 3 hours before coming to the clinic, sampling just after arrival at clinic, 5 hours post-dose, 8-10 hours post-dose (if participants remained at clinic)</time_frame>
        <population>The PK analysis population included all participants randomized and treated with fesoterodine and who had at least 1 of the PK parameters of primary interest during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine Pooled</title>
            <description>Participants received any dose of fesoterodine in the study from Week 1 to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Absorption Rate Constant (Ka) of Fesoterodine</title>
          <description>Absorption rate constant is used to determine rate at which drug is entering into body. Pharmacokinetic (PK) analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.</description>
          <population>The PK analysis population included all participants randomized and treated with fesoterodine and who had at least 1 of the PK parameters of primary interest during the study.</population>
          <units>per hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0897" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance (CL/F) of Fesoterodine</title>
        <description>Clearance determines the rate at which a drug is metabolized or eliminated by normal biological processes. PK analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.</description>
        <time_frame>Week 4, Day 1: pre-dose (when dose administered at clinic) or if dose taken at home up to 3 hours before coming to the clinic, sampling just after arrival at clinic, 5 hours post-dose, 8-10 hours post-dose (if participants remained at clinic)</time_frame>
        <population>The PK analysis population included all participants randomized and treated with fesoterodine and who had at least 1 of the PK parameters of primary interest during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine Pooled</title>
            <description>Participants received any dose of fesoterodine in the study from Week 1 to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) of Fesoterodine</title>
          <description>Clearance determines the rate at which a drug is metabolized or eliminated by normal biological processes. PK analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.</description>
          <population>The PK analysis population included all participants randomized and treated with fesoterodine and who had at least 1 of the PK parameters of primary interest during the study.</population>
          <units>liter per hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Vd) of Fesoterodine</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PK analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.</description>
        <time_frame>Week 4, Day 1: pre-dose (when dose administered at clinic) or if dose taken at home up to 3 hours before coming to the clinic, sampling just after arrival at clinic, 5 hours post-dose, 8-10 hours post-dose (if participants remained at clinic)</time_frame>
        <population>The PK analysis population included all participants randomized and treated with fesoterodine and who had at least 1 of the PK parameters of primary interest during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine Pooled</title>
            <description>Participants received any dose of fesoterodine in the study from Week 1 to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vd) of Fesoterodine</title>
          <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PK analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.</description>
          <population>The PK analysis population included all participants randomized and treated with fesoterodine and who had at least 1 of the PK parameters of primary interest during the study.</population>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 26 (includes 2 week of follow up)</time_frame>
      <desc>Same event may appear as AE and serious AE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as non-serious in another participant or 1 participant may have experienced both serious and non-serious event during study. Safety analysis population evaluated.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg</title>
          <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in active comparator phase.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1, Active Comparator Phase: Fesoterodine 4 mg Then 8 mg</title>
          <description>Participants with body weight &gt;25 kg were randomized to receive fesoterodine 4 mg PR tablets orally once daily for first 1 week and if dose was tolerated well, participants received 8 mg PR tablet orally once daily for next 11 weeks in active comparator phase and if dose was not tolerated then participants were withdrawn from the study.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1, Active Comparator Phase: Oxybutynin</title>
          <description>Participants with body weight &gt;25 kg were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice. Dose titration was done for first 4 weeks. After Week 4, participants remained on the optimized daily dose for next 8 weeks, in active comparator phase.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 1, Safety Extension Phase: Fesoterodine 4 mg</title>
          <description>Participants with body weight &gt;25 kg received fesoterodine 4 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 1, Safety Extension Phase (SEP): Fesoterodine 8 mg</title>
          <description>Participants with body weight &gt;25 kg received fesoterodine 8 mg PR tablet orally once daily for 12 weeks in safety extension phase.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 1, SEP: Oxybutynin Then Fesoterodine 4 mg</title>
          <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for 12 weeks in the safety extension phase.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 1,SEP: Oxybutynin Then Fesoterodine 8 mg</title>
          <description>Participants with body weight &gt;25 kg who were randomized to receive oxybutynin ER tablet, at a daily dose in accordance with approved pediatric labeling and accepted practice, in active comparator phase; were allocated by investigator to receive fesoterodine 4 mg PR tablet orally once daily for first 1 week followed by fesoterodine 8 mg PR tablet orally once daily for another 11 weeks (if the fesoterodine 4 mg dose was well tolerated) in the safety extension phase and if dose was not tolerated participants were withdrawn from the study.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 2, Efficacy Phase: Fesoterodine 2 mg</title>
          <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for 12 weeks in efficacy phase.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 2 Efficacy Phase: Fesoterodine 4 mg</title>
          <description>Participants with body weight &lt;=25 kg were randomized to receive fesoterodine 2 mg BIC capsule orally once daily for first 1 week and if dose was tolerated well, participants received 4 mg BIC capsule orally once daily for next 11 weeks in efficacy phase and if dose was not tolerated then participants were withdrawn from the study.</description>
        </group>
        <group group_id="E10">
          <title>Cohort 2, Safety Extension Phase: Fesoterodine 2 mg</title>
          <description>Participants with body weight &lt;=25 kg received fesoterodine 2 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
        </group>
        <group group_id="E11">
          <title>Cohort 2, Safety Extension Phase: Fesoterodine 4 mg</title>
          <description>Participants with body weight &lt;=25 kg received fesoterodine 4 mg BIC capsules orally once daily for 12 weeks in safety extension phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Complicated appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Epiphysiolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="14" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Accommodation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Lip erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Infection parasitic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Ear lobe infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cystitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Investigation abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Residual urine volume increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urine output increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cystogram</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Spinal deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Behaviour disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Encopresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Skin odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Wheelchair user</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

